arlene h. naranjo · 2019-08-07 · publications 1. kibria, b. and naranjo, a. (2002). testing the...

Research Associate Professor

University of Florida

Colleges of Medicine and Public Health & Health Professions

Department of Biostatistics

Children’s Oncology Group (COG) Statistics & Data Center

6011 NW 1st Place, Suite 10

Gainesville, FL 32607

Phone: 352.273.0577

E‐mail: [email protected]

Arlene H. Naranjo

Education

2002 – 2007 University of Florida (UF) Gainesville, FL

Doctor of Philosophy, Statistics

Dissertation topic: “State‐Space Models with Exogenous Variables and Missing Data.” Longitudinal data analysis with

missing values from a state‐space perspective. Includes theoretical and applied sections, with simulation studies and

analysis of auto‐immune diseases patient data related to research assistantship position.

2000 – 2002 Florida International University Miami, FL

Master of Science, Statistics

Thesis title: ʺInferences About the Scale Parameter of the Gamma Distribution Based on Grouped and Partially Censored

Dataʺ


Bachelor of Science, Mathematical Sciences

Relevant Experience

2019 – Present UF Children’s Oncology Group Gainesville, FL

Research Associate Professor

Design pediatric oncology clinical trials in neuroblastoma and renal tumors

Conduct Kaplan‐Meier survival analysis and Cox proportional hazards modeling

Prepare technical reports and write statistical methodology and results sections for scientific papers

Graduate Faculty status, for the purpose of serving on graduate students’ supervisory committees

2008 – 2019 UF Children’s Oncology Group Gainesville, FL

Research Assistant Professor

Design pediatric oncology clinical trials in neuroblastoma and renal tumors

Conduct Kaplan‐Meier survival analysis and Cox proportional hazards modeling

Prepare technical reports and write statistical methodology and results sections for scientific papers

Graduate Faculty status, for the purpose of serving on graduate students’ supervisory committees

2006 – 2007 University of Florida Gainesville, FL

Graduate Research Assistant

Prepared data collected from a pediatrics and an education study for analysis

Conducted t‐test, Wilcoxon rank sum, ANOVA, Kruskal‐Wallis, regression, cluster, hierarchical linear model (HLM),

receiver operating characteristic (ROC) curve, and area under the ROC curve analyses in SAS

Presented results and developed topics for publication at team meetings

Wrote statistical methodology and results sections in papers submitted for publication


Graduate Research Assistant

Prepared data collected from patients with auto‐immune diseases for analysis

Conducted correlation, weighted regression, repeated measures, longitudinal, receiver operating characteristic (ROC)

curve, and area under the ROC curve analyses in SAS

Worked in a team environment to develop topics for research and publication

Wrote statistical methodology and results section in papers submitted for publication


Graduate Teaching Assistant

Taught 4 weekly sessions to complement introductory statistics course lectures

Graded lab assignments, held office hours, and conducted exam review sessions

Summer 2002 Florida International University Miami, FL

Adjunct Instructor

Taught Introduction to Statistics course

Wrote, conducted, and graded quizzes and exams


Graduate Teaching Assistant

Taught Introduction to Statistics during Fall and Spring semesters

Graded student homework for other professors in the Department of Statistics

Held tutoring sessions for students in lower‐level statistics courses

Summers, 2000 – 2002 Assurant Group Miami, FL

Actuarial Intern

Prepared new insurance product packages for filing in each state

Conducted research for the development of new insurance products

Professional Activities Member of the American Statistical Association

Member of the Society for Clinical Trials

Reviewer for Pediatric Blood & Cancer

Reviewer for Statistics in Medicine

Awards University of Florida Faculty Enhancement Opportunity (FEO) award (Fall 2012), intended to advance the

academic/professional/scholarly activities and contribute to the professional career goals of faculty members

GlaxoSmithKline Scholar Award (2002‐2003), given each year to the most promising first‐year graduate student in

the Department of Statistics at the University of Florida

Languages/Skills Fluent in Spanish

SAS, R/S‐Plus

Microsoft Office package (Word, Excel, Access, PowerPoint)

LaTex

Research Interests Clinical Trials Design & Analysis

Survival Analysis

Longitudinal Data Analysis

Hierarchical Linear Models

Publications 1. Kibria, B. and Naranjo, A. (2002). Testing the Mean of Skewed Distributions: Chen’s t2 Test Revisited, Pakistan

Journal of Statistics 18(2): 213–224.

2. Mi, J. and Naranjo, A. (2003). Inferences About the Scale Parameter of the Gamma Distribution Based on Data

Mixed from Censoring and Grouping, Statistics & Probability Letters 62: 229–243.

3. Barnes, E., Narain, S., Naranjo, A., Shuster, J., Segal, M., Sobel, E., Armstrong, A., Santiago, B., Reeves, W., and

Richards, H. (2005). High Sensitivity C‐Reactive Protein in Systemic Lupus Erythematosus: Relation to Disease

Activity, Clinical Presentation and Implications for Cardiovascular Risk, Lupus 14(8): 576–582.

4. Vermeulen, J., De Preter, K., Naranjo, A., Vercruysse, L., Van Roy, N., Hellemans, J., Swerts, K., Bravo, S.,

Scaruffi, P., Tonini, G.P., Noguera, R., Piqueras, M., Janoueix‐Lerosey, I., Delattre, O., Combaret, V., Fischer, M.,

Oberthuer, A., Ambros, P., Beiske, K., Bénard, J., Marques, B., Michon, J., Schleiermacher, G., De Bernardi, B.,

Rubie, H., Cañete, A., Castel, V., Kohler, J., Pötschger, U., Ladenstein, R., Hogarty, M.D., McGrady, P., London,

W.B., Laureys, G., Speleman, F., and Vandesompele, J. (2009). Predicting Outcomes for Children with

Neuroblastoma using a Multigene‐Expression Signature: A Retrospective SIOPEN/COG/GPOH Study, The Lancet

Oncology 10(7): 663–671.

5. Okamatsu, C., London, W.B., Naranjo, A., Hogarty, M.D., Gastier‐Foster, J.M., Look, A.T., LaQuaglia, M., Maris,

J.M., Cohn, S.L., Matthay, K.K., Seeger, R.C., Saji,T., and Shimada, H. (2009). Clinicopathological Characteristics

of Ganglioneuroma and Ganglioneuroblastoma: A Report from the CCG and COG Studies, Pediatric Blood &

Cancer 53(4): 563–569.

6. Naranjo, A., Parisi, M.T., Shulkin, B.L., London, W.B., Matthay, K.K., Kreissman, S.G., and Yanik, G.A. (2011).

Comparison of 123I‐Metaiodobenzylguanidine (MIBG) and 131I‐MIBG Semi‐Quantitative Scores in Predicting

Survival in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group, Pediatric Blood &

Cancer 56(7): 1041–1045. DOI: 10.1002/pbc.22991.

7. Liu, Z., Naranjo, A., and Thiele, C.J. (2011). CASZ1b, the Short Isoform of CASZ1 Gene, Coexpresses with

CASZ1a during Neurogenesis and Suppresses Neuroblastoma Cell Growth, PLos ONE 6(4): e18557. DOI:

10.1371/journal.pone.0018557.

8. Park, J.R., Scott, J., Stewart, C.F., London, W.B., Naranjo, A., Santana, V.M., Shaw, P.J., Cohn, S.L, and Matthay,

K.K. (2011). Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of

Newly Diagnosed High Risk Neuroblastoma: A Children’s Oncology Group Study (ANBL02P1). Journal of Clinical

Oncology 29(33): 4351–4357. DOI: 10.1200/JCO.2010.34.3293.

9. Villablanca, J.G., London, W.B., Naranjo, A., McGrady, P., Ames, M.M., Reid, J.M., McGovern, R.M., Buhrow,

S.A., Jackson, H., Stranzinger, E., Kitchen, B.J., Sondel, P.M., Parisi, M.T., Shulkin, B., Yanik, G.A., Cohn, S.L., and

Reynolds, C.P. (2011). Phase II Study of Oral Capsular 4‐Hydroxyphenylretinamide (4‐HPR/Fenretinide) in

Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Childrenʹs Oncology Group.

Clinical Cancer Research 17(21): 6858–6866. DOI: 10.1158/1078‐0432.CCR‐11‐0995.

10. De Preter, K., Mestdagh, P., Vermeulen, J., Zeka, F., Naranjo, A., Bray, I., Castel, V., Chen, C., Drozynska, E.,

Eggert, A., Hogarty, M.D., Izycka‐Swieszewska, E., London, W.B., Noguera, R., Piqueras, M., Bryan, K., Schowe,

B., Van Sluis, P., Molenaar, J.J., Schramm, A., Schulte, J.H., Stallings, R.L., Versteeg, R., Laureys, G., Van Roy, N.,

Speleman, F., and Vandesompele, J. (2011). miRNA Expression Profiling Enables Risk Stratification in Archived

and Fresh Neuroblastoma Tumor Samples. Clinical Cancer Research 17(24): 7684–7692. DOI: 10.1158/1078‐

0432.CCR‐11‐0610.

11. Daunic, A.P., Smith, S.W., Garvan, C.W., Barber, B.R., Becker, M.K., Peters, C.D., Taylor, G.G., Van Loan, C.L., Li,

W., and Naranjo, A.H. (2012). Reducing Developmental Risk for Emotional/Behavioral Problems: A Randomized

Controlled Trial Examining the Tools for Getting Along Curriculum. Journal of School Psychology 50(2): 149‐166.

DOI: 10.1016/j.jsp.2011.09.003.

12. Turnbull, C., Perdeaux, E.R., Pernet, D., Naranjo, A., Renwick, A., Seal, S., Munoz‐Xicola, R.M., Hanks, S., Slade,

I., Zachariou, A., Warren‐Perry, M., Ruark, E., Gerrard, M., Hale, J., Hewitt, M., Kohler, J., Lane, S., Levitt, G.,

Madi, M., Morland, B., Neefjes, V., Nicholdson, J., Picton, S., Pizer, B., Ronghe, M., Stevens, M., Traunecker, H.,

Stiller, C.A., Pritchard‐Jones, K., Dome, J., Grundy, P., and Rahman, N. (2012). A Genome‐Wide Association

Study Identifies Susceptibility Loci for Wilms Tumor. Nature Genetics 44(6): 681–684. DOI: 10.1038/ng.2251.

13. Granger, M., Grupp, S.A., Kletzel, M., Kretschmar, C., Naranjo, A., London, W.B., and Diller, L. (2012). Feasibility

of a Tandem Autologous Peripheral Blood Stem Cell Transplant Regimen for High Risk Neuroblastoma in a

Cooperative Group Setting: A Pediatric Oncology Group Study: A Report from the Childrenʹs Oncology Group.

Pediatric Blood & Cancer 59(5): 902–907. DOI: 10.1002/pbc.24207.

14. Khanna, G., Naranjo, A., Hoffer, F., Mullen, E., Geller, J., Gratias, E.J., Ehrlich, P.F., Perlman, E.J., Rosen, N.,

Grundy, P., and Dome, J.S. (2013). Detection of Preoperative Wilms Tumor Rupture with CT: A Report from the

Children’s Oncology Group. Radiology 266(2): 610‐7. DOI: 10.1148/radiol.12120670.

15. Suganuma, R., Wang, L.L., Sano, H., Naranjo, A., London, W.B., Seeger, R.C., Hogarty, M.D., Gastier‐Foster, J.M.,

Look, A.T., Park, J.R., Maris, J.M., Cohn, S.L., Amann, G., Beiske, K., Cullinane, C.J., d’Amore, E.S.G., Gambini, C.,

Jarzembowski, J.A., Joshi, V.V., Navarro, S., Peuchmaur, M., and Shimada, H. (2013). Peripheral Neuroblastic

Tumors with Genotype‐Phenotype Discordance: A Report from the Children’s Oncology Group and the

International Neuroblastoma Pathology Committee. Pediatric Blood & Cancer 60(3): 363‐70. DOI: 10.1002/pbc.24238.

16. Ostler, K.R., Yang, Q., Looney, T.J., Zhang, L., Vasanthakumar, A., Tian, Y., Kocherginsky, M., Raimondi, S.L.,

DeMaio, J.G., Salwen, H.R., Gu, S., Chlenski, A., Naranjo, A., Gill, A., Peddinti, R., Lahn, B.T., Cohn, S.L., and

Godley, L.A. (2012). Truncated DNMT3B Isoform DNMT3B7 Suppresses Growth, Induces Differentiation and

Alters DNA Methylation in Human Neuroblastoma. Cancer Research 72(18): 4714‐4723. DOI: 10.1158/0008‐5472.CAN‐12‐0886.

17. Nuchtern, J.G., London, W.B., Barnewolt, C.E., Naranjo, A., McGrady, P.W., Geiger, J.D., Diller, L., Schmidt, M.L.,

Maris, J.M., Cohn, S.L., and Shamberger, R.C. (2012). A Prospective Study of Expectant Observation as Primary

Therapy for Neuroblastoma in Young Infants, a Children’s Oncology Group Study. Annals of Surgery 256(4): 573–

580. DOI: 10.1097/SLA.0b013e31826cbbbd.

18. Gow, K.W., Barnhart, D.C., Hamilton, T.E., Kandel, J.J., Chen, M.K.S., Ferrer, F.A., Price, M.R., Mullen, E.A.,

Geller, J.I., Gratias, E.J., Rosen, N., Khanna, G., Naranjo, A., Ritchey, M.L., Grundy, P.E., Dome, J.S., and Ehrlich,

P.F. (2013). Primary Nephrectomy and Intraoperative Tumor Spill: Report from the Childrenʹs Oncology Group

(COG) Renal Tumors Committee. Journal of Pediatric Surgery 48(1): 34‐8. DOI: 10.1016/j.jpedsurg.2012.10.015.

19. DuBois, S.G., Geier, E., Batra, V., Yee, S.W., Neuhaus, J., Segal, M., Martinez, D., Pawel, B., Yanik, G., Naranjo, A.,

London, W.B., Kreisman, S., Baker, D., Attiyeh, E., Hogarty, M., Maris, J.M., Giacomini, K., and Matthay, K.K.

(2012). Evaluation of Norepinephrine Transporter Expression and Avidity for Metaiodobenzylguanidine (MIBG)

in Patients with Neuroblastoma: A Report from the Children’s Oncology Group. International Journal of Molecular

Imaging, 2012: 8 pages. DOI: 10.1155/2012/250834.

20. Yanik, G.A., Parisi, M.T., Shulkin, B.L., Naranjo, A., Kreissman, S.G., London, W.B., Villablanca, J.G., Maris, J.M.,

Park, J.R., Cohn, S.L., McGrady, P., and Matthay, K.K. (2013). Semiquantitative MIBG Scoring as a Prognostic

Indicator in Patients with Stage 4 Neuroblastoma. A Report from the Children’s Oncology Group. Journal of

Nuclear Medicine 54(4): 541‐548. DOI: 10.2967/jnumed.112.112334.

21. Naranjo, A., Trindade, A.A., and Casella, G. (2013). Extending the State‐Space Model to Accommodate Missing

Values in Responses and Covariates. Journal of the American Statistical Association 108(501): 202‐216. DOI:

10.1080/01621459.2012.746066.

22. Dome, J.S., Fernandez, C.V., Mullen, E.A., Kalapurakal, J.A., Geller, J.I., Huff, V., Gratias, E.J., Dix, D.B., Ehrlich,

P.F., Khanna, G., Malogolowkin, M.H., Anderson, J.R., Naranjo, A., and Perlman, E.J., on behalf of the COG Renal

Tumors Committee (2013). Children’s Oncology Group’s 2013 Blueprint for Research: Renal Tumors. Pediatric

Blood & Cancer 60(6): 994‐1000. DOI: 10.1002/pbc.24419.

23. Seif, A.E., Naranjo, A., Baker, D.L., Bunin, N.J., Kletzel, M., Kretschmar, C.S., London, W.B., Maris, J.M., Park,

J.R., Diller, L.R., and Grupp, S.A. (2013). A Pilot Study of Tandem High Dose Chemotherapy with Stem Cell

Rescue as Consolidation for High‐Risk Neuroblastoma: Children’s Oncology Group Study ANBL00P1. Bone

Marrow Transplantation 48(7): 947–952. DOI: 10.1038/bmt.2012.276.

24. Levy, A.S., Pyke‐Grimm, K.A., Lee, D.A., Palla, S.L., Naranjo, A., Sholler, G.S., Gratias, E., Maloney, K.,

Parshankar, F., Lee‐Scott, M., Beierle, E.A., Gow, K., Kim, G.E., Hunger, S., Smith, F.O., and Horton, T. (2013).

Mentoring in Pediatric Oncology: A Report from the Children’s Oncology Group Young Investigator Committee.

Journal of Pediatric Hematology & Oncology 35(6): 456–461. DOI: 10.1097/MPH.0b013e31829eec33.

25. Wang, L.L., Suganunma, R., Ikegaki, N., Tang, X., Naranjo, A., London, W.B., Hogarty, M.D., Gastier‐Foster, J.M.,

Look, A.T., Park, J.R., Maris, J.M., Cohn, S.L., Seeger, R.C., and Shimada, H. (2013). Neuroblastoma of

Undifferentiated Subtype, Prognostic Significance of Prominent Nucleolar Formation, and MYC/MYCN Protein

Expression: A Report from the Children’s Oncology Group. Cancer 119(20): 3718‐26. DOI: 10.1002/cncr.28251.

26. Hamilton, T.E., Barnhart, D., Gow, K., Ferrer, F., Kandel, J., Glick, R., Dasgupta, R., Naranjo, A., He, Y., Gratias,

E., Geller, J., Mullen, E., and Ehrlich, P. (2014). Inter‐rater Reliability of Surgical Reviews for AREN03B2: A COG

Renal Tumor Committee Study. Journal of Pediatric Surgery 49(1): 154‐158. DOI: 10.1016/j.jpedsurg.2013.09.047.

27. Karlsson, J., Mengelbier, L.H., Ciornei, C., Naranjo, A., O’Sullivan, M.J., and Gisselsson, D. (2014). Clear Cell

Sarcoma of the Kidney Demonstrates an Embryonic Signature Indicative of a Primitive Nephrogenic Origin.

Genes, Chromosomes & Cancer 53(5): 381‐91. DOI: 10.1002/gcc.22149.

28. Libes, J.M., Seeley, E.H., Li, M., Axt, J.R., Pierce, J., Correa, H., Newton, M., Hansen, E., N’Dungu, J., Oruko, O.,

Githanga, J., Abdullah, F., Musimbi, J., Njuguna, F., Patel, K., Ellsworth, G., Mwachiro, M., White, R., Judd, A.,

McDonald, H., Caprioli, R.M., Naranjo, A., Huff, V., O’Neill, J.A., and Lovvorn, H.N. (2014). Race Disparities in

Peptide Profiles of North American and Kenyan Wilms Tumor Specimens. Journal of the American College of

Surgeons 218(4): 707‐20. DOI: 10.1016/j.jamcollsurg.2013.12.044.

29. Ferrer, F.A., Herbst, K.W., Fernandez, C.V., Khanna, G., Dome, J.S., Naranjo, A., Mullen, E.A., Geller, J.I., Gratias,

E., Shamberger, R., Ritchey, M., and Ehrlich, P.F. (2014). Feasibility of Using CT Volume as a Predictor of

Specimen Weight in a Subgroup of Patients with Low Risk Wilms Tumors Registered on COG Study AREN03B2:

Implications for Central Venous Catheter Placement. Journal of Pediatric Urology 10(5): 969‐73. DOI:

10.1016/j.jpurol.2014.02.006.

30. Servaes, S., Khanna, G., Naranjo, A., Geller, J.I., Ehrlich, P., Gow, K., Perlman, E., Dome, J.S., and Mullen, E.

(2014). Comparison of Diagnostic Performance of CT and MRI for Abdominal Staging of Pediatric Renal Tumors:

A Report from the Children’s Oncology Group. Pediatric Radiology 45(2): 166‐72. DOI: 10.1007/s00247‐014‐3138‐2.

31. Teshiba, R., Kawano, S., Wang, L.L., He, L, Naranjo, A., London, W.B., Seeger, R.C., Gastier‐Foster, J.M., Look,

A.T., Hogarty, M.D., Cohn, S.L., Maris, J.M., Park, J.R., and Shimada, H. (2014). Age‐Dependent Prognostic Effect

by Mitosis‐Karyorrhexis Index in Neuroblastoma: A Report from the Children’s Oncology Group. Pediatric and

Developmental Pathology 17: 441‐9. DOI: 10.2350/14‐06‐1505‐OA.1.

32. Geller, J.I., Ehrlich, P.F., Cost, N.G., Khanna, G., Mullen, E.A., Gratias, E.J., Naranjo, A., Dome, J.S., Perlman, E.J.

(2015). Characterization of Adolescent and Pediatric Renal Cell Carcinoma, a Report from the Children’s

Oncology Group Study AREN03B2. Cancer 121(14): 2457‐64. DOI: 10.1002/cncr.29368.

33. Wang, L.L., Teshiba, R., Ikegaki, N., Tang, X.X., Naranjo, A., London, W.B., Hogarty, M.D., Gastier‐Foster, J.M.,

Look, A.T., Park, J.R., Maris, J.M., Cohn, S.L., Seeger, R.C., Asgharzadeh, S., and Shimada, H. (2015). Augmented

Expression of MYC and/or MYCN Protein Defines Highly Aggressive MYC‐Driven Neuroblastoma: A Childrenʹs

Oncology Group Study. British Journal of Cancer 113(1): 57‐63. DOI: 10.1038/bjc.2015.188.

34. Eleveld, T.F., Oldridge, D.A., Bernard, V., Koster, J., Daage, L.C., Diskin, S.J., Schild, L., Bentahar, N.B., Bellini, A.,

Chicard, M., Lapouble, E., Combaret, V., Legoix‐Né, P., Michon, J., Pugh, T.J., Hart, L.S., Rader, J., Attiyeh, E.F.,

Wei, J.S., Zhang, S., Naranjo, A., Gastier‐Foster, J.M., Hogarty, M.D., Smith, M.A., Auvil, J.M.G., Watkins, T.B.K.,

Zwijnenburg, D.A., Ebus, M.E., van Sluis, P., Hakkert, A., van Wezel, E., van der Schoot, C.E., Westerhout, E.M.,

Schulte, J.H., Tytgat, G.A., Dolman, M.E.M., Janoueix‐Lerosey, I., Gerhard, D.S., Caron, H.N., Delattre, O., Khan,

J., Versteeg, R., Schleiermacher, G., Molenaar, J.J., and Maris, J.M. (2015). Relapsed Neuroblastomas Show

Frequent RAS‐MAPK Pathway Mutations. Nature Genetics 47(8): 864‐71. DOI: 10.1038/ng.3333.

35. Temple, W., Mendelsohn, L., Kim, G.E., Nekritz, E., Gustafson, W.C., Lin, L., Giacomini, K., Naranjo, A., Van

Ryn, C., Yanik, G.A., Kreissman, S.G., Hogarty, M., Matthay, K.K., and DuBois, S.G. (2016). Vesicular Monoamine

Transporter Protein Expression Correlates with Clinical Features, Tumor Biology, and MIBG Avidity in

Neuroblastoma: A Report from the Children’s Oncology Group. European Journal of Nuclear Medicine and

Molecular Imaging 43(3): 474‐81. DOI: 10.1007/s00259‐015‐3179‐2.

36. Bagatell, R., McHugh, K., Naranjo, A., Van Ryn, C., Kirby, C., Brock, P., Lyons, K.A., States, L.J., Rojas, Y., Miller,

A., Volchenboum, S.L., Simon, T., Krug, B., Sarnacki, S., Valteau‐Couanet, D., von Schweinitz, D., Kammer, B.,

Granata, C., Pio, L., Park, J.R., and Nuchtern, J. (2016). Assessment of Primary Site Response in Children with

High‐Risk Neuroblastoma: An International Multicenter Study. Journal of Clinical Oncology 34(7): 740‐6. DOI:

10.1200/JCO.2015.63.2042.

37. Ehrlich, P.F., Hamilton, T.E., Gow, K., Barnhart, D., Ferrer, F., Kandel, J., Glick, R., Dasgupta, R., Naranjo, A., He,

Y., Perlman, E.J., Kalapurakal, J.A., Khanna, G., Dome, J.S., Geller, J., and Mullen, E. (2016). Surgical Protocol

Violations in Children with Renal Tumors Provides an Opportunity to Improve Pediatric Cancer Care: A Report

from the Childrenʹs Oncology Group. Pediatric Blood & Cancer 63(11): 1905‐10. DOI: 10.1002/pbc.26083.

38. Galli, S., Naranjo, A., Van Ryn, C., Tilan, J., Trinh, E., Yang, C., Tsuei, J., Hong, S., Wang, H., Izycka‐Swieszewska,

E., Rodriguez, O., Albanese, C., and Kitlinska, J. (2016). Neuropeptide Y as a Biomarker and Therapeutic Target

for Neuroblastoma. American Journal of Pathology 186(11): 3040‐53. DOI: 10.1016/j.ajpath.2016.07.019.

39. Mazul, A.L., Siega‐Riz, A.M., Weinberg, C.R., Engel, S.M., Zou, F., Carrier, K.S., Basta, P.V., Maris, J.M., Diskin,

S.J., Vaksman, Z., Maxen, C., Naranjo, A., and Olshan, A.F. (2016). A Family‐Based Study of Gene Variants and

Maternal Folate and Choline in Neuroblastoma: A Report from the Children’s Oncology Group. Cancer Causes and

Control 27(10): 1209‐18. DOI: 10.1007/s10552‐016‐0799‐1.

40. Applebaum, M.A., Vaksman, Z., Hungate, E.A., Henderson, T.O., London, W.B., Pinto, N., Volchenboum, S.L.,

Park, J.R., Naranjo, A., Hero, B., Pearson, A.D., Cohn, S.L., and Diskin, S.J. (2017). Neuroblastoma Survivors are at

Increased Risk for Second Malignancies: A Report from the International Neuroblastoma Risk Group Project.

European Journal of Cancer 72: 177–85. DOI: 10.1016/j.ejca.2016.11.022.

41. DuBois, S.G., Mody, R., Naranjo, A., Van Ryn, C., Russ, D., Oldridge, D., Kreissman, S., Baker, D.L., Parisi, M.,

Shulkin, B., Bai, H., Diskin, S., Batra, V., Maris, J.M., Park, J.R., Matthay, K.K., and Yanik, G. (2017). MIBG Avidity

Correlates with Clinical Features, Tumor Biology, and Outcomes in Neuroblastoma: A Report from the Children’s

Oncology Group. Pediatric Blood & Cancer 64(11): e26545. DOI: 10.1002/pbc.26545.

42. Mody, R., Naranjo, A., Van Ryn, C., Yu, A.L., London, W.B., Shulkin, B.L., Parisi, M.T., Servaes, S., Diccianni,

M.B., Reisfeld, R.A., Gillies, S.D., Sondel, P.M., Maris, J.M., Park, J.R., and Bagatell, R. (2017). Irinotecan–

Temozolomide with Temsirolimus or Dinutuximab in Children with Refractory or Relapsed Neuroblastoma

(COG ANBL1221): An Open‐Label, Randomised, Phase 2 Trial. Lancet Oncology 18(7): 946‐57. DOI: 10.1016/S1470‐

2045(17)30355‐8.

43. Erbe, A.K., Wang, W., Reville, P.K., Carmichael, L., Kim, K., Mendonca, E.A., Song, Y., Hank, J.A., London, W.B.,

Naranjo, A., Hong, F., Hogarty, M.D., Maris, J.M., Park, J.R., Ozkaynak, M.F., Miller, J.S., Gilman, A.L., Kahl, B.,

Yu, A.L., and Sondel, P.M. (2017). HLA‐Bw4‐I‐80 Isoform Differentially Influences Clinical Outcome as

Compared to HLA‐Bw4‐T‐80 and HLA‐A‐Bw4 Isoforms in Rituximab or Dinutuximab‐Based Cancer

Immunotherapy. Frontiers in Immunology 8: 675. DOI: 10.3389/fimmu.2017.00675.

44. Campbell, K., Gastier‐Foster, J., Naranjo, A., Van Ryn, C., Bagatell, R., Matthay, K.K., London, W.B., Hogarty, M.,

Park, J.R., and DuBois, S.G. (2017). Association of MYCN Copy Number with Clinical Features, Tumor Biology,

and Outcomes in Neuroblastoma: A Report from the Children’s Oncology Group. Cancer 123(21): 4224‐35.

45. London, W.B., Bagatell, R., Weigel, B.J., Fox, E., Guo, D., Van Ryn, C., Naranjo, A., Krailo, M., and Park, J.R.

(2017). Historical Time to Disease Progression and Progression‐Free Survival in Patients with Recurrent/

Refractory Neuroblastoma Treated in the Modern Era on Childrenʹs Oncology Group Early‐Phase Trials. Cancer

123(24): 4914–23. DOI: 10.1002/cncr.30934.

46. Yanik, G.A., Parisi, M.T., Naranjo, A., Nadel, H., Gelfand, M.J., Park, J.R., Ladenstein, R.L., Poetschger, U.,

Boubaker, A., Valteau‐Couanet, D., Lambert, B., Castellani, M., Bar‐Sever, Z., Oudoux, A., Kaminska, A.,

Kreissman, S.G., Shulkin, B.L., and Matthay, K.K. (2017). Validation of Post‐Induction Curie Scores in High‐Risk

Neuroblastoma: A Children’s Oncology Group (COG) and SIOPEN Group Report on SIOPEN/HR‐NBL‐1. Journal

of Nuclear Medicine 59(3): 502‐8. DOI: 10.2967/jnumed.117.195883.

47. Erbe, A.K., Wang, W., Carmichael, L., Kim, K., Mendonça, E.A., Song, Y., Hess, D., Reville, P.K., London, W.B.,

Naranjo, A., Hank, J.A., Diccianni, M.B., Reisfeld, R.A., Gillies, S.D., Matthay, K.K., Cohn, S.L., Hogarty, M.D.,

Maris, J.M., Park, J.R., Ozkaynak, M.F., Gilman, A.L., Yu, A.L., and Sondel, P.M. (2018). Neuroblastoma Patients’

KIR and KIR‐ligand Genotypes Influence Clinical Outcome for Dinutuximab‐Based Immunotherapy: A Report

from the Childrenʹs Oncology Group. Clinical Cancer Research 24(1): 189‐96. DOI: 10.1158/1078‐0432.CCR‐17‐1767.

48. Ladenstein, R. and Lambert, B., Pötschger, U., Lewington, V., Castellani, M., Bar‐Sever, Z., Oudoux, A.,

Kaminska, A., Taborska, K., Biassoni, L., Yanik, G.A., Naranjo, A., Parisi, M.T., Shulkin, B.L., Nadel, H., Gelfand,

M.J., Matthay, K.K., Park, J.R., Kreissman, S.G., Valteau‐Couanet, D., and Boubaker, A. (2018). Validation of the

mIBG Skeletal SIOPEN Scoring Method in Two Independent High Risk Neuroblastoma Populations: The COG‐

A3973 and SIOPEN/HR‐NBL1 Trials. European Journal of Nuclear Medicine and Molecular Imaging 45(2): 292‐305.

DOI: 10.1007/s00259‐017‐3829‐7.

49. De Alarcon, P.A., Matthay, K.K., London, W.B., Naranjo, A., Tenney, S.C., Panzer, J.A., Hogarty, M.D., Park, J.R.,

Maris, J.M., and Cohn, S.L. (2018). Intravenous Immunoglobulin with Prednisone and Risk‐Adapted

Chemotherapy for Children with Opsoclonus Myoclonus Ataxia Syndrome Associated with Neuroblastoma

(ANBL00P3): A Randomised, Open‐Label, Phase 3 Trial. The Lancet Child & Adolescent Health 2(1): 25‐34. DOI:

10.1016/S2352‐4642(17)30130‐X.

50. Niemas‐Teshiba, R., Matsuno, R., Wang, L.L., Tang, X.X., Chiu, B., Zeki, J., Coburn, J., Ornell, K., Naranjo, A.,

Van Ryn, C., London, W.B., Hogarty, M.D., Gastier‐Foster, J.M., Look, A.T., Park, J.R., Maris, J.M., Cohn, S.L.,

Seeger, R.C., Asgharzadeh, S., Ikegaki, N., and Shimada, H. (2018). MYC‐Family Protein Overexpression and

Prominent Nucleolar Formation Represent Prognostic Indicators and Potential Therapeutic Targets for

Aggressive High‐MKI Neuroblastomas: A Report from the Children’s Oncology Group. Oncotarget 9(5): 6416–32.

51. Naranjo, A., Irwin, M.S., Hogarty, M.D., Cohn, S.L., Park, J.R., and London, W.B. (2018). Statistical Framework for

the Revised International Neuroblastoma Risk Group Staging System (INRGSS) Risk Classification System. JCO

Clinical Cancer Informatics 2: 1‐15. DOI: 10.1200/CCI.17.00140.

52. Ozkaynak, M.F., Gilman, A.L., Yu, A.L., London, W.B., Naranjo, A., Tenney, S., Diccianni, M.B., Smith, M.,

Messer, K.S., Seeger, R., Reynolds, C.P., Smith, L.M., Shulkin, B.L., Parisi, M., Maris, J.M., Park, J.R., and Sondel,

P.M. (2018). A Comprehensive Safety Trial of Ch14.18 with GM‐CSF, IL‐2 and Isotretinoin in High‐Risk

Neuroblastoma Patients Following Myeloablative Therapy: Childrenʹs Oncology Group Study ANBL0931.

Frontiers in Immunology 9:1355. DOI: 10.3389/fimmu.2018.01355.

53. Alexander, N., Marrano, P., Thorner, P., Naranjo, A., Van Ryn, C., Martinez, D., Batra, V., Zhang, L., Irwin, M.S.,

and Baruchel, S. (2019). Prevalence and Clinical Correlations of Somatostatin Receptor‐2 (SSTR2) Expression in

Neuroblastoma. Journal of Pediatric Hematology and Oncology 41(3): 222‐7. DOI: 10.1097/MPH.0000000000001326.

54. Twist, C., Naranjo, A., Schmidt, M.L., Tenney, S.C., Cohn, S., Meany, H., Mattei, P., Adkins, E.S., Shimada, H.,

London, W.B., Park, J.R., Matthay, K.K., and Maris, J.M. (2019). Defining Risk Factors for Chemotherapeutic

Intervention in Infants with Stage 4S Neuroblastoma: A Report from the Children’s Oncology Group. Journal of

Clinical Oncology 37(2): 115‐24. DOI: 10.1200/JCO.18.00419.

55. Pinto, N., Naranjo, A., Hibbitts, E., Kreissman, S.G., Granger, M.M., Irwin, M.S., Bagatell, R., London, W.B.,

Greengard, E.G., Park, J.R., and DuBois, S.G. (2019). Predictors of Differential Response to Induction

Chemotherapy in High‐Risk Neuroblastoma: A Report from the Children’s Oncology Group (COG). European

Journal of Cancer 112: 66‐79. DOI: 10.1016/j.ejca.2019.02.003.

56. Shusterman, S., Naranjo, A., Van Ryn, C., Hank, J.A., Parisi, M.T., Shulkin, B.L., Servaes, S., London, W.B.,

Shimada, H., Gan, J., Gillies, S.D., Maris, J.M., Park, J.R., and Sondel, P.M. (2019). Anti‐Tumor Activity and

Tolerability of the hu14.18‐IL2 Immunocytokine in Combination with GM‐CSF and Isotretinoin in Recurrent or

Refractory Neuroblastoma Patients: A Children’s Oncology Group (COG) Phase II Study, ANBL1021. Clinical

Cancer Research.

57. Twist, C.J., Schmidt, M.L., Naranjo, A., London, W.B., Tenney, S.C., Marachelian, A., Shimada, H., Collins, M.,

Esiashvili, N., Adkins, E.S., Mattei, P., Handler, M., Katzenstein, H., Attiyeh, E., Hogarty, M.D., Gastier–Foster, J.,

Matthay, K.K., Park, J.R., Maris, J.M., and Cohn, S.L. (2019). Maintaining Outstanding Outcomes using Response

and Biology‐based Therapy for Intermediate‐Risk Neuroblastoma: A Report from the Children’s Oncology

Group Study ANBL0531. Journal of Clinical Oncology.

58. Mazul, A.L., Weinberg, C.R., Engel, S.M., Siega‐Riz, A.M., Zou, F., Carrier, K.S., Basta, P.V., Vaksman, Z., Maris,

J.M., Diskin, S.J., Maxen, C., Naranjo, A., and Olshan, A.F. (2019). Neuroblastoma in Relation to Joint Effects of

Vitamin A and Maternal and Offspring Variants in Vitamin A‐Related Genes: A Report of the Children’s

Oncology Group. Cancer Epidemiology 61: 165‐71. DOI: 10.1016/j.canep.2019.06.009.

59. Ortiz, M.V., Ahmed, S., Burns, M., Henssen, A., Hollmann, T., MacArthur, I., Gunasekera, S., Gaewsky, L.,

Bradwin, G., Ryan, J., Letai, A., He, Y., Naranjo, A., Chi, Y., LaQuaglia, M., Heaton, T., Cifani, P., Dome, J., Gadd,

S., Perlman, E., Mullen, E., Steen, H., and Kentsis, A. Prohibitin is a Prognostic Marker of Relapse and Therapeutic

Target to Block Chemotherapy Resistance in Wilms Tumor. JCI Insight.

60. Park, J.R., Kreissman, S.G., London, W.B., Naranjo, A., Cohn, S.L., Hogarty, M.D., Tenney, S.C., Haas‐Kogan, D.,

Shaw, P.J., Kraveka, J.M., Roberts, S.S., Geiger, J.D., Doski, J.J., Gorges, S.W., Khanna, G., Voss, S.D., Maris, J.M.,

Grupp, S.A., and Diller, L. Effect of Tandem Autologous Stem Cell Transplantation vs. Single Transplantation on

Event‐Free Survival in Patients with High‐Risk Neuroblastoma: A Randomized Clinical Trial. Journal of the

American Medical Association.

Submitted 1. Zeineldin, M., Federico, S., Chen, X., Fan, Y., Xu, B., Stewart, E., Jeon, J., Griffiths, L., Easton, J., Mulder, H.,

Yergeau, D., Wu, J., Mao, S., Naranjo, A., Hogarty, M.D., Kaminski, M., Green, D., Valentine, M., Miller, S.,

Pappo, A., Zhang, J., Clay, M., Bahrami, A., Mardis, E.R., Wilson, R.K., Downing, J.R., and Dyer, M.A. MYCN

Amplification and ATRX Mutations Are Incompatible in Neuroblastoma. Nature Communications.

2. Balis, F.M., Busch, C., Desai, A.V., Hibbitts, E., Naranjo, A., Bagatell, R., Irwin, M., and Fox, E. The Ganglioside,

GD2, as a Circulating Tumor Biomarker for Neuroblastoma. Pediatric Blood & Cancer.

3. Liu, Y., Brady, S., Ma, X., Hagiwara, K., Easton, J., Mulder, H., Naranjo, A., Cheng, C., Cheung, N., Pugh, T.,

Maris, J., Downing, J., Dyer, M., and Hogarty, M. Pan‐Neuroblastoma Sequencing Reveals Age‐ and ROS‐

Associated Drivers and ALK N‐Terminal Structural Alterations. Nature Genetics.

In Revision 1. Bona, K., Li, Y., Huang, Y., Getz, K.D., Winestone, L.E., Fisher, B.T., Desai, A.V., Hall, M., Naranjo, A.,

Henderson, T., Aplenc, R., and Bagatell, R. Poverty and Precision‐Medicine: Survival in Children with High‐Risk

Neuroblastoma Treated on Children’s Oncology Group Clinical Trials ANBL0032 and 0931.

2. Cho, H., Sonawane, P., Naranjo, A., Van Ryn, C., Yang, S., Yu, A.L., Park, J.R., Kreisman, S., Villablanca, J.G.,

Reynolds, C.P., and Kang, M.H. Low Plasma Levels of 13‐Cis‐Retinoic Acid (Isoretinoin) and its Active Metabolite

4‐Oxo‐13‐Cis‐Retinoic Acid Are Associated with Lower Overall Survival of High‐Risk Neuroblastoma Patients.

3. Roberts, J.K., Wu, W., Wu, J., Naranjo, A., Daryani, V.M., Gajjar, A.J., Park, J.R., and Stewart, C.F. Population

Pharmacokinetics of Topotecan in a Pediatric High‐Risk Neuroblastoma Clinical Trial Utilizing a Single Sample

Approach.

4. Daunic, A.P., Naranjo, A., Garvan, C.W., and Smith, S.W. Use of Behavioral Assessments from Multiple

Informants to Identify Children at Risk for Externalizing Behavior Problems. School Psychology Review.

Abstracts 1. Yanik, G.A., Parisi, M.T., Naranjo, A., Matthay, K.K., London, W.B., McGrady, P.W., Kreissman, S.G., and

Shulkin, B.L. (2010). MIBG Scoring as a Prognostic Indicator in Patients with Stage IV Neuroblastoma: A COG

Study. Journal of Clinical Oncology 28(15_suppl): 9516. DOI: 10.1200/jco.2010.28.15_suppl.9516. Oral presentation at

American Society of Clinical Oncology (ASCO) 2010 annual meeting.

2. Parisi, M., Shulkin, B., Naranjo, A., McGrady, P., London, W., Kreissman, S., and Yanik, G. (2010). MIBG Scores:

A Means of Identifying an Ultra‐High Risk Group of Patients. Journal of Nuclear Medicine 51(supplement 2): 490.

Oral presentation at Society of Nuclear Medicine 2010 meeting.

3. Parisi, M., Shulkin, B., Naranjo, A., McGrady, P., London, W., Kreissman, S., and Yanik, G. (2010). Impact of

MIBG Scores on Predicting Survival in High Risk Neuroblastoma Patients. Journal of Nuclear Medicine

51(supplement 2): 491. Oral presentation at Society of Nuclear Medicine 2010 meeting.

4. Suganuma, R., Sano, H., Wang, L.L., Tovar, J.P., Naranjo, A., London, W.B., Seeger, R.C., Hogarty, M.D., Gastier‐

Foster, J.M., Look, T.A., Park, J.R., Maris, J.M., Cohn, S.L., Amann, G., Beiske, K., Cullinane, C.J., dʹAmore, E.S.G.,

Gambini, C., Jarzembowski, J.A., Joshi, V.V., Navarro, S., Peuchmaur, M., and Shimada, H. (2011). Peripheral

Neuroblastic Tumors with Genotype‐Phenotype Discordance: A Report from Childrenʹs Oncology Group and

International Neuroblastoma Pathology Committee. Pediatric & Developmental Pathology 14(6): 502. Oral

presentation at Society for Pediatric Pathology 2011 fall meeting.

5. Ehrlich, P., Cost, N., Khanna, G., Mullen, E., Gratias, E., Naranjo, A., Dome, J., Perlman, E., and Geller, J. (2012).

A Description of the Surgical Experience in Children, Adolescents and Young Adults with Renal Cell Carcinoma:

A Report from the Children’s Oncology Group Study AREN03B2. BJU International 110(s2): 18. Poster

presentation at International Kidney Cancer Symposium 2012 meeting.

6. Geller, J., Mullen, E., Khanna, G., Ehrlich, P., Cost, N., Naranjo, A., Dome, J., Gratias, E., and Perlman, E. (2012).

Epidemiology and Characterization of Pediatric and Adolescent Renal Cell Carcinoma: A Report from the

Childrenʹs Oncology Group Study AREN03B2. BJU International 110(s2): 18‐9. Poster presentation at International

Kidney Cancer Symposium 2012 meeting.

7. Ostler, K.R., Yang, Q., Vasanthakumar, A., Zhang, L., Looney, T.J., Naranjo, A., Salwen, H., Kocherginsky, M.,

Lahn, B.T., Cohn, S.L., and Godley, L.A. (2012). A Truncated DNMT3B Protein (DNMT3B7) Drives DNA

Methylation and Suppresses Growth in Human Neuroblastoma. Cancer Research 72(8 Suppl): 1040. DOI:

10.1158/1538‐7445.AM2012‐1040. Poster presentation at American Association for Cancer Research (AACR) 2012

annual meeting.

8. Meany, H.J., Attiyeh, E.F., Naranjo, A., Twist, C., London, W.B., Villablanca, J., Schmidt, M.L., Baker, D., Strother,

D.R., Shimada, H., Matthay, K.K., Cohn, S.L., Maris, J.M., and Park, J.R. (2012). Outcome Analysis of Non‐High‐

Risk Neuroblastoma Patients Enrolled on Children’s Oncology Group Trials P9641 and A3961. Journal of Clinical

Oncology 30(15_suppl): 9533. DOI: 10.1200/jco.2012.30.15_suppl.9533. Poster presentation at American Society of

Clinical Oncology (ASCO) 2012 annual meeting.

9. Nuchtern, J.G., London, W.B., Barnewolt, C.E., Naranjo, A., Geiger, J.D., Cohn, S.L., and Shamberger, R.C. (2012).

A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants, a

Children’s Oncology Group Study. Pediatric Blood & Cancer 59(6): 1059. DOI: 10.1002/pbc.24295. Poster

presentation at 2012 congress of the International Society of Paediatric Oncology (SIOP).

10. Kawano, S., Wang, L., Naranjo, A., London, W.B., Hogarty, M.D., Gastier‐Foster, J.M., Look, A.T., Park, J.R.,

Maris, J.M., Cohn, S.L., Seeger, R., and Shimada, H. (2013). Mitosis‐Karyorrhexis Index (MKI) and MYC Status in

Neuroblastoma, with a Special Reference to Intermediate MKI: A Report from the Children’s Oncology Group

(COG). Pediatric & Developmental Pathology 16(2): 124. Oral presentation at Society for Pediatric Pathology 2013

spring meeting.

11. Kentsis, A., Burns, M., Eisenberg, A., Ahmed, S., Gaewsky, L., Bradwin, G., He, Y., Naranjo, A., Gadd, S., Warren,

P., Rodriguez‐Galindo, C., Dome, J., Perlman, E., Steen, H., and Mullen, E. (2013). Prohibitin is a Prognostic

Marker of Treatment Failure and Therapeutic Target to Block Chemotherapy Resistance in Wilms Tumor.

Pediatric Blood & Cancer 60(S2): S3. DOI: 10.1002/pbc.24509. Oral presentation at American Society of Pediatric

Hematology/Oncology (ASPHO) 2013 annual meeting.

12. Wang, L.L., Teshiba, R., He, L., Naranjo, A., London, W.B., Gastier‐Foster, J.M., Seeger, R.C., Cohn, S.L., Maris,

J.M., Park, J.R., Hogarty, M.D., and Shimada, H. (2014). MYCN/MYC Protein Expression in High‐MKI (Mitosis‐

Karyorrhexis Index) Neuroblastomas: A Report from the Children’s Oncology Group. Cancer Research 74(20

Supplement): B40. DOI: 10.1158/1538‐7445.pedcan‐B40. Poster presentation at American Association for Cancer

Research (AACR) 2013 Special Conference – Pediatric Cancer at the Crossroads: Translating Discovery into

Improved Outcomes.

13. London, W.B., Bagatell, R., Weigel, B., Fox, E., Van Ryn, C., Naranjo, A., Krailo, M.D., Ahern, C.H., and Park, J.R.

(2014). Historical Gold Standard for Time‐to‐Progression (TTP) and Progression‐Free Survival (PFS) from

Relapsed/Refractory Neuroblastoma Modern Era (2002‐14) Patients. Pediatric Blood & Cancer 61(S2): S123. DOI:

10.1002/pbc.25314. Oral presentation at 2014 congress of the International Society of Paediatric Oncology (SIOP).

14. Mullen, E.A., Geller, J.J., Gratias, E., Perlman, E.J., Ehrlich, P.F., Khanna, G., Naranjo, A., Fernandez, C.V., Gow,

K., Ferrer, F., Hamilton, T., Glick, R., Kandel, J., Barnhart, D., He, Y., Dasgupta, R., Hoffer, F., Servaes, S., Gastier‐

Foster, J., Hill, D.A., Huff, V., Grundy, P., and Dome, J. (2014). Comprehensive Update of Pediatric Renal Tumor

Epidemiology: Analysis of the First 4000 Patients on Children’s Oncology Group (COG) Renal Tumor

Classification and Biology Protocol AREN03B2. Pediatric Blood & Cancer 61(S2): S166. DOI: 10.1002/pbc.25314. Oral

presentation at 2014 congress of the International Society of Paediatric Oncology (SIOP).

15. Ehrlich, P.F., Mullen, E., Geller, J., Naranjo, A., Gratias, E., Barnhart, D., Dasgupta, R., Ferrar, F., Gow, K.,

Hamilton, T., Kandel, J., He, Y., Perlman, E., Khanna, G., Hoffer, F., Servaes, S., Kalapurakal, J., and Dome, J.S.

(2014). Unilateral Wilms Tumor Treated by Partial Nephrectomy Enrolled on the Childrenʹs Oncology Group

(COG) Renal Tumor Biology and Classification Study AREN03B2. Pediatric Blood & Cancer 61(S2): S112‐3. DOI:

10.1002/pbc.25314. Oral presentation at 2014 congress of the International Society of Paediatric Oncology (SIOP).

16. Paulino, A.C., Gratias, E.J., Fernandez, C.V., Ehrlich, P.F., Gow, K.W., Naranjo, A., Perlman, E.J., Dome, J.S., and

Kalapurakal, J.A. (2014). Outcomes and Patterns of Failure after Preoperative Chemotherapy for Favorable

Histology Wilms Tumor on National Wilms Tumor Study (NWTS)‐5. International Journal of Radiation Oncology,

Biology, Physics 90(1): S116. DOI: 10.1016/j.ijrobp.2014.05.545. Oral presentation at American Society for Radiation

Oncology (ASTRO) 2014 annual meeting.

17. Boubaker, A., Pötschger, U., Lambert, B., Castellani, M.R., Bar‐Sever, Z., Oudoux, A., Kaminska, A., Taborska, K.,

Kreissman, S.G., Yanik, G., Matthay, K.K., Naranjo, A., Park, J.R., Valteau‐Couanet, D., and Ladenstein, R. (2014).

Validation of the mIBG SIOPEN Scoring Method in 2 Independent High Risk Neuroblastoma Trial Populations.

European Journal of Nuclear Medicine and Molecular Imaging 41(Supplement 2): S220. DOI 10.1007/s00259‐014‐2901‐

9. Oral presentation at 2014 annual congress of the European Association of Nuclear Medicine (EANM).

18. MacLellan, D., Karakach, T., Naranjo, A., and Fernandez, C.V. (2014). Urinary Metabolite Profiling by Nuclear

Magnetic Resonance Spectroscopy to Distinguish Control Patients from Wilms Tumor (WT) and WT Tumor by

Stage. Journal of Clinical Oncology 32(15_suppl): e21013. Publication only ‐ American Society of Clinical Oncology

(ASCO) 2014 annual meeting.

19. Yanik, G.A., Naranjo, A., Parisi, M.T., Shulkin, B.L., Nadal, H.R., Gelfand, M.J., Ladenstein, R.L., Boubaker, A.,

Poetschger, U., Lambert, B., Castellani, M.R., Valteau‐Couanet, D., Kreissman, S.G., Park, J.R., and Matthay, K.K.

(2014). Validation of Post‐Induction Curie Scores in High‐Risk Neuroblastoma. Journal of Clinical Oncology

32(15_suppl): 10031. Poster presentation at American Society of Clinical Oncology (ASCO) 2014 annual meeting.


(2014). Historical Gold Standard for Time‐to‐Progression (TTP) and Progression‐Free Survival (PFS) from

Relapsed/Refractory Neuroblastoma Modern Era (2002‐14) Patients. Journal of Clinical Oncology 32(15_suppl):

10034. Poster presentation at American Society of Clinical Oncology (ASCO) 2014 annual meeting.

21. Mullen, E.A., Geller, J.I., Gratias, E.J., Perlman, E.J., Ehrlich, P.F., Khanna, G., Naranjo, A., He, Y., Hamilton, T.E.,

Ferrer, F.A., Glick, R.D., Gow, K.W., Barnhardt, D.C., Kandel, J.J., Dasgupta, R., Hoffer, F.A., Serveas, S.,

Fernandez, C.V., Grundy, P.E., and Dome, J. (2014). Real‐Time Central Review: A Report of the First 3,000

Patients Enrolled on the Children’s Oncology Group Renal Tumor Biology and Risk Stratification Protocol

AREN03B2. Journal of Clinical Oncology 32(15_suppl): 10000. Oral presentation at American Society of Clinical

Oncology (ASCO) 2014 annual meeting.

22. Twist, C., London, W.B., Naranjo, A., Schmidt, M.L., Adkins, E.S., Mattei, P., Cretella, S., Cohn, S.L., Park, J.R.,

and Maris, J.M. (2014, May 31; Oral). Maintaining Outstanding Outcomes using Response‐ and Biology‐Based

Therapy for Intermediate‐Risk Neuroblastoma: A Report from the Children’s Oncology Group Study ANBL0531.

Journal of Clinical Oncology 32(15_suppl): 10006. Oral presentation at American Society of Clinical Oncology


23. Boubaker, A., Pötschger, U., Lambert, B., Castellani, M.R., Bar‐Sever, Z., Oudoux, A., Kaminska, A., Taborska, K.,

Biassoni, L, Kreissman, S.G., Yanik, G.A., Naranjo, A., Parisi, M.T., Shulkin, B.L., Matthay, K.K., Park, J.R.,

Valteau‐Couanet, D., and Ladenstein, R.L. (2014). Validation of the MIBG SIOPEN Scoring Method in Two

Independent High‐Risk Neuroblastoma Trials. Journal of Clinical Oncology 32(15_suppl): 10029. Poster

presentation at American Society of Clinical Oncology (ASCO) 2014 annual meeting.

24. DuBois, S.G., Temple, W., Mendelsohn, L., Kim, G.E., Nekritz, E., Gustafson, C., Lin, L., Giacomini, K., Naranjo,

A., Van Ryn, C., Yanik, G.A., Kreissman, S.G., Hogarty, M.D., and Matthay, K.K. (2015). Vesicular Monoamine

Transporter Protein Expression in Neuroblastoma: A Report from the Children’s Oncology Group. Journal of

Clinical Oncology 33(15_suppl): 10043. Poster presentation at American Society of Clinical Oncology (ASCO) 2015

annual meeting.

25. Applebaum, M.A., Henderson, T.O., London, W.B., Pinto, N.R., Volchenboum, S.L., Park, J.R., Naranjo, A.,

Pearson, A.D.J., Hero, B., Diskin, S., and Cohn, S.L. (2015). Second Malignancies in Neuroblastoma Patients: A

Report from the International Neuroblastoma Risk Group Project. Journal of Clinical Oncology 33(15_suppl): 10019.

Poster presentation at American Society of Clinical Oncology (ASCO) 2015 annual meeting.

26. Shusterman, S., London, W.B., Hank, J.A., Parisi, M.T., Shulkin, B.L., Servaes, S., Naranjo, A., Shimada, H., Gan,

J., Gillies, S., Maris, J.M., Park, J.R., and Sondel, P.M. (2015). A Feasibility and Phase II Study of the hu14.18‐IL2

Immunocytokine in Combination with GM‐CSF and Isotretinoin in Patients with Recurrent or Refractory

Neuroblastoma: A Children’s Oncology Group Study. Journal of Clinical Oncology 33(15_suppl): 10017. Oral


27. Galli, S., Tilan, J., Naranjo, A., Van Ryn, C., Yang, C., Tsuei, J., Trinh, E., and Kitlinska, J. (2015). Association of Neuropeptide Y (NPY) and its Receptors with Prognostic Factors and Survival in Neuroblastoma Patients.

Laboratory Investigation 95: 468A. Oral presentation at United States and Canadian Academy of Pathology

(USCAP) 2015 annual meeting.

28. Yanik, G., Naranjo, A., Parisi, M.T., Shulkin, B.L., Nadel, H., Gelfand, M.J., Ladenstein, R., Boubaker, A.,

Poetschger, U., Valteau‐Couanet, D., Kreissman, S.G., Park, J.R., and Matthay, K.K. (2015). Impact of Post‐

Induction Curie Scores in High‐Risk Neuroblastoma. Biology of Blood and Marrow Transplantation 21(2,

Supplement): S107. DOI: 10.1016/j.bbmt.2014.11.131. Oral presentation at American Society for Blood and

Marrow Transplantation (ASBMT) 2015 tandem meeting.

29. Galli, S., Tilan, J., Naranjo, A., Van Ryn, C., Yang, C., Tsuei, J., Trinh, E., and Kitlinska, J.B. (2015). Neuropeptide

Y (NPY) and its Receptor Expression in Neuroblastoma Patients – Associations with Disease Prognosis and

Patientsʹ Survival. Cancer Research 75(15, Supplement): 1628. DOI: 10.1158/1538‐7445.AM2015‐1628. Poster

presentation at American Association for Cancer Research (AACR) 2015 annual meeting.

30. Oldridge, D.A., Eleveld, T.F., Bernard, V., Koster, J., Daage, L.C., Diskin, S.J., Schild, L., Bentahar, N.B., Bellini, A.,


Wei, J.S., Zhang, S., Naranjo, A., Gastier‐Foster, J.M., Hogarty, M.D., Smith, M.A., Auvil, J.G., Watkins, T.B.K.,



J., Versteeg, R., Schleiermacher, G., Maris, J.M., and Molenaar, J.J. (2015). Relapsed Neuroblastomas Show

Frequent RAS‐MAPK Pathway Mutations. Cancer Research 75(15, Supplement): 2980. DI 10.1158/1538‐

7445.AM2015‐2980. Poster presentation at American Association for Cancer Research (AACR) 2015 annual

meeting.


Look, A.T., Park, J.R., Maris, J.M., Cohn, S.L., Seeger, R.C., Asgharzadeh, S., and Shimada, H. (2015).

Immunohistochemical Detection of MYCN Protein and MYC Protein Identifies Highly Aggressive

Neuroblastomas. Molecular Cancer Research 13(10, Supplement): A37. DOI: 10.1158/1557‐3125.MYC15‐A37. Poster

presentation at American Association for Cancer Research (AACR) 2015 Special Conference on MYC: From

Biology to Therapy.

32. Nuchtern, J., Bagatelle, R., McHugh, K., Naranjo, A., Van Ryn, C., Rojas, Y., Lyons, K., Guillerman, P., Kirby, C.,

Brock, P., Volchenboum, S., Simon, T., States, L., Miller, A., Krug, B., Sarnaki, S., Valteau‐Couannet, D., von

Schweinitz, D., Kammer, B., Granata, C., Pio, L., and Park, J. (2015). A Subset of Image Defined Risk Factors

Predicts Completeness of Resection in Children with High‐Risk Neuroblastoma: An International Multicenter

Study. Pediatric Blood & Cancer 62(S4): S185. Oral presentation at 2015 congress of the International Society of

Paediatric Oncology (SIOP).

33. Teshiba, R., Wang, L., Ikegaki, N., Tang, X.X., Naranjo, A., London, W.B., Hogarty, M.D., Gastier‐Foster, J.M.,

Look, A.T., Park, J.R., Maris, J., Cohn, S.L., Seeger, R.C., Asgharzadeh, S., and Shimada, H. (2015).

Immunohistochemical Profile of MYCN/MYC Protein Expression in Neuroblastoma with High Mitosis‐

Karyorrhexis Index: A Report from the Children’s Oncology Group Neuroblastoma Study. Pediatric &

Developmental Pathology 18(2): e3. Oral presentation at Society for Pediatric Pathology 2015 spring meeting.

34. Park, J.R., Kreissman, S.G., London, W.B., Naranjo, A., Cohn, S.L., Hogarty, M.D., Teeney, S.C., Haas‐Kogan, D.,

Shaw, P.J., Geiger, J.D., Doski, J.J., Gorges, S.W., Khanna, G., Voss, S.D., Maris, J.M., Grupp, S.A., and Diller, L.

(2016). A Phase III Randomized Clinical Trial (RCT) of Tandem Myeloablative Autologous Stem Cell Transplant

(ASCT) Using Peripheral Blood Stem Cell (PBSC) as Consolidation Therapy for High‐Risk Neuroblastoma (HR‐

NB): A Children’s Oncology Group (COG) Study. Journal of Clinical Oncology 34(15_suppl): LBA3. DOI:

10.1200/JCO.2016.34.15_suppl.LBA3. Plenary session oral presentation at American Society of Clinical Oncology


35. DuBois, S.G., Mody, R., Van Ryn, C., Naranjo, A., Kreissman, S.G., Baker, D., Parisi, M.T., Shulkin, B.L., Maris,

J.M., Batra,V., Park, J.R., Matthay, K.K., and Yanik, G.A. (2016). Clinical, Biologic, and Outcome Differences

According to MIBG Avidity in Children with Neuroblastoma: A Report from the Children’s Oncology Group

(COG). Journal of Clinical Oncology 34(15_suppl): 10526. DOI: 10.1200/JCO.2016.34.15_suppl.10526. Poster


36. Pinto, N.R., Emond, M.J., Spiekerman, C., Naranjo, A., Makar, K.W., Park, J., and McCune, J.S. (2016).

Pharmacogenetics of Treatment Response in Patients with High‐Risk Neuroblastoma, A Children’s Oncology

Group Study. Journal of Clinical Oncology 34(15_suppl): 10560. DOI: 10.1200/JCO.2016.34.15_suppl.10560. Poster


37. Federico, S.M., Chen, X., Easton, J., Wu, J., Mao, S., Liu, Y., Naranjo, A., Pappo, A.S., Hogarty, M.D., and Dyer,

M.A. (2016). Association of Age at Diagnosis and Stage of Disease with ATRX Mutations in Neuroblastoma.

Journal of Clinical Oncology 34(15_suppl): 10525. DOI: 10.1200/JCO.2016.34.15_suppl.10525. Poster presentation at

American Society of Clinical Oncology (ASCO) 2016 annual meeting.


M.B., Sondel, P.M., Maris, J.M., Park, J.R., and Bagatell, R. (2016). Phase II Randomized Trial of Irinotecan/

Temozolomide (I/T) with Temsirolimus (TEM) or Dinutuximab Plus Granulocyte Colony Stimulating Factor

(DIN/GMCSF) in Children with Refractory or Relapsed Neuroblastoma: A Report from the Children’s Oncology

Group (COG). Journal of Clinical Oncology 34(15_suppl): 10502. DOI: 10.1200/JCO.2016.34.15_suppl.10502. Oral


39. Applebaum, M.A., Vaksman, Z., Hungate, E., Henderson, T.O., London, W.B., Pinto, N.R., Volchenboum, S.L.,

Park, J.R., Naranjo, A., Pearson, A.D.J., Hero, B., Cohn, S.L., and Diskin, S. (2016). Second Malignancies in

Patients with Neuroblastoma: A Report from the International Neuroblastoma Risk Group Project. Journal of

Clinical Oncology 34(15_suppl): 10547. DOI: 10.1200/JCO.2016.34.15_suppl.10547. Poster presentation at American

Society of Clinical Oncology (ASCO) 2016 annual meeting.

40. Granger, M., Yanik, G.A., Naranjo, A., McCune, J.S., Dubois, S.G., Bagatell, R., Weiss, B.D., Grupp, S.A., Tenney,

S.C., Asgharzadeh, S., Hogarty, M.D., Panoff, J.E., Chang, J.H., Gastier‐Foster, J.M., Mills, D., and Park, J.R. (2016).

Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with

High‐Risk Neuroblastoma: A Children’s Oncology Group (COG) Study. Journal of Clinical Oncology 34(15_suppl):

10528. DOI: 10.1200/JCO.2016.34.15_suppl.10528. Poster presentation at American Society of Clinical Oncology


41. Irwin, M.S., Naranjo, A., Van Ryn, C., Cohn, S.L., London, W.B., Gastier‐Foster, J., Matthay, K.K., Attiyeh, E.F.,

Maris, J.M., Bagatell, R., Park, J.R., and Hogarty, M.D. (2016). Revised Children’s Oncology Group (COG) Risk

Stratification Incorporating the International Neuroblastoma Risk Group Staging System. Pediatric Blood & Cancer

63(S3): S29. Oral presentation at 2016 congress of the International Society of Paediatric Oncology (SIOP).

42. Granger, M., Naranjo, A., McCune, J.S., Dubois, S.G., Bagatell, R., Weiss, B.D., Grupp, S.A., Cretella, S., Mosse,

Y.P., Asgharzadeh, S., Hogarty, M., Panoff, J., Chang, J.H., London, W., Gastier‐Foster, J.M., Mills, D., Park, J.R.,

and Yanik, G. (2016). Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction

Chemotherapy for Patients with High‐Risk Neuroblastoma. A Children’s Oncology Group (COG) Study. Pediatric

Blood & Cancer 63(S3): S39. Oral presentation at 2016 congress of the International Society of Paediatric Oncology

(SIOP).

43. Pötschger, U., Naranjo, A., Yanik, G., Castellani, M., Boubaker, A., Lambert, B., Lewington, V., Kaminska, A.,

Taborska, K., Parisi, M., Shulkin, B., Park, J., Kreissman, S., Matthay, K., and Ladenstein, R. (2016). The Way

Towards an International mIBG Skeletal Score for High Risk Neuroblastoma: The Statistical Perspective. Pediatric

Blood & Cancer 63(S3): S39‐S40. Oral presentation at 2016 congress of the International Society of Paediatric

Oncology (SIOP).


Taborska, K., Parisi, M., Shulkin, B., Park, J., Kreissman, S., Matthay, K., and Ladenstein, R. (2016). Towards an

International mIBG Skeletal Score for High Risk Neuroblastoma: A SIOPEN‐COG Cooperation. European Journal

of Nuclear Medicine and Molecular Imaging 43(Supplement 1): S31‐S32. DOI: 10.1007/s00259‐016‐3484‐4. Oral

presentation at European Association of Nuclear Medicine 2016 annual congress.

45. Pötschger, U., Naranjo, A., Yanik, G., Castellani, M., Boubaker, A., Lambert, B., Lewington, V., Bar‐Sever, Z.,

Oudoux, A., Kaminska, A., Taborska, K., Biassoni, L., Parisi, M., Shulkin, B., Nadel, H., Gelfand, M., Park, J.,

Kreissman, S., Valteau‐Couanet, D., Matthay, K., and Ladenstein, R. (2017). The Way Towards an International

mIBG Skeletal Score for High Risk Neuroblastoma: The Statistical Perspective. Monatsschr Kinderheilkd 165(Suppl

2): S113. DOI: 10.1007/s00112‐017‐0357‐2. Oral presentation at Austrian Society for Pediatrics and Adolescent

Medicine 2017 annual meeting.

46. Erbe, A.K., Wang, W., Carmichael, L., Kim, K., Reville, P.K., London, W.B., Hank, J.A., Diccianni, M.B., Naranjo,

A., Hogarty, M.D., Park, J.R., Yu, A.L., and Sondel, P.M. (2017). Impact of KIR/KIR Ligand Genotype for

Neuroblastoma Patients in a Phase 3 COG Immunotherapy Trial. Cancer Research 77(13, Supplement): LB‐048.

DOI: 10.1158/1538‐7445.AM2017‐LB‐048. Poster presentation at American Association for Cancer Research

(AACR) 2017 annual meeting.

47. Cho, H., Naranjo, A., Van Ryn, C., Yang, S., Sonawane, P., Villablanca, J.G., Yu, A.L., Park, J.R., Kreissman, S.,

Reynolds, C.P., and Kang, M.H. (2017). Low Plasma Levels of 13‐Cis‐Retinoic Acid (Isotretinoin) and its Active

Metabolite 4‐Oxo‐13‐Cis‐Retinoic Acid Are Associated with Lower Overall Survival of High‐Risk Neuroblastoma

Patients. Cancer Research 77(13, Supplement): LB‐049. DOI: 10.1158/1538‐7445.AM2017‐LB‐049. Poster


48. Ortiz, M.V., Burns, M., Eisenberg, A., Ahmed, S., Gaewsky, L., Bradwin, G., Cifani, P., Henssen, A., Macarthur, I.,

LaQuaglia, M., Letai, A., Naranjo, A., Gadd, S., Chi, Y., Dome, J., Perlman, E., Mullen, E., Steen, H., and Kentsis,

A. (2017). Prohibitin is a Prognostic Marker of Treatment Failure and Therapeutic Target to Block Chemotherapy

Resistance in Wilms Tumor. Cancer Research 77(13, Supplement): 708. DOI: 10.1158/1538‐7445.AM2017‐708. Poster


49. Diccianni, M.B., Mielke, J., Williams, R., Messer, K., Ozkaynak, F., Gilman, A.L., Naranjo, A., London, W., Sondel,

P.M., Park, J., Yu, A.L., and Childrens Oncology Group (2018). Natural Antibodies to Non‐Human Glycans

Neu5Gc and Alpha‐Gal Correlate with Outcome of High‐Risk Neuroblastoma Patients Treated with Dinutuximab

on COG ANBL0032 and ANBL0931. Cancer Research 78(13, Supplement): LB‐300. DOI: 10.1158/1538‐

7445.AM2018‐LB‐300. Poster presentation at American Association for Cancer Research (AACR) 2018 annual

meeting.

50. Zeineldin, M., Federico, S., Chen, X., Xu, B., Stewart, E., Naranjo, A., Hogarty, M.D., and Dyer, M.A. (2018).

MYCN Amplification and ATRX Mutations Are Incompatible in Neuroblastoma. Cancer Research 78(19,

Supplement): Abstract nr IA18. DOI: 10.1158/1538‐7445.PEDCA17‐IA18. Oral presentation at American

Association for Cancer Research (AACR) 2017 Special Conference – Pediatric Cancer Research: From Basic

Science to the Clinic.

51. Zeineldin, M., Federico, S.M., Griffith, L., Jeon, J., Chen, X., Easton, J., Wu, J., Mao, S., Liu, Y., Naranjo, A., Pappo,

A.S., Hogarty, M.D., and Dyer, M.A. (2018). Synthetic Lethality Between ATRX Mutations and MYCN

Amplification in Neuroblastoma. Cancer Research 78(19, Supplement): Abstract nr PR11. DOI: 10.1158/1538‐

7445.PEDCA17‐PR11. Oral presentation at American Association for Cancer Research (AACR) 2017 Special

Conference – Pediatric Cancer Research: From Basic Science to the Clinic.

52. Balis, F.M., Busch, C., Desai, A.V., Hibbitts, E., Naranjo, A., Bagatell, R., Irwin, M., and Fox, E. (2018). GD2 as a

Circulating Tumor Biomarker (CTB) for Neuroblastoma (NBL). Journal of Clinical Oncology 36(15 suppl): 10538.

DOI: 10.1200/JCO.2018.36.15_suppl.10538. Poster presentation at American Society of Clinical Oncology (ASCO)

2018 annual meeting.

53. Mody, R., Naranjo, A., Yu, A.L., Hibbitts, E., London, W.B., Shulkin, B.L., Parisi, M.T., Servaes, S., Diccianni, M.B.,

Sondel, P.M., Glade‐Bender, J., Katzenstein, H., Maris, J., Park, J.R., and Bagatell, R. (2018). Phase II Trial of

Irinotecan/Temozolomide/Dinutuximab/Granulocyte Macrophage Colony Stimulating Factor (I/T/DIN/GMCSF)

in Children with Relapsed/Refractory Neuroblastoma (NBL): A Report from The Childrenʹs Oncology Group

(COG). Journal of Clinical Oncology 36(15 suppl): 10508. DOI: 10.1200/JCO.2018.36.15_suppl.10508. Oral


54. Pinto, N.R., Hibbitts, E., Kreissman, S.G., Granger, M.P., Irwin, M., Bagatell, R., London, W.B., Greengard, E.G.,

Naranjo, A., Park, J.R., and DuBois, S.G. (2018). Predictors of Differential Response to Induction Chemotherapy in

High‐Risk Neuroblastoma: A Report from the Childrenʹs Oncology Group (COG). Journal of Clinical Oncology

36(15 suppl): 10532. DOI: 10.1200/JCO.2018.36.15_suppl.10532. Poster presentation at American Society of Clinical

Oncology (ASCO) 2018 annual meeting.

55. Bona, K., Li, Y., Huang, Y., Getz, K.D., Winestone, L.E., Fisher, B.T., Desai, A.V., Hall, M., Naranjo, A.,

Henderson, T., Aplenc, R., and Bagatell, R. (2019). Poverty and Survival in Targeted Immunotherapy Clinical

Trials. Journal of Clinical Oncology 37(15 suppl): 10034. DOI: 10.1200/JCO.2019.37.15_suppl.10034. Poster


56. Irwin, M.S., Naranjo, A., Cohn, S.L., London, W.B., Gastier‐Foster, J., Maris, J.M., Bagatell, R., Park, J.R., and

Hogarty, M.D. (2019). Revised Children’s Oncology Group (COG) Neuroblastoma Risk Classification System: A

Report from COG ANBL00B1. Journal of Clinical Oncology 37(15 suppl): 10012. DOI: 10.1200/JCO.2019.37.

15_suppl.10012. Oral presentation at American Society of Clinical Oncology (ASCO) 2019 annual meeting.

Presentations 1. Naranjo, A. (2009, September 30; Oral). The Youden Index, Children’s Oncology Group Fall 2009 Meeting, Dallas,

TX.

2. Naranjo, A., Parisi, M.T., Shulkin, B.L., London, W.B., Matthay, K.K., Kreissman, S.G., and Yanik, G.A. (2010, June

22; Poster). Comparison of I‐123 and I‐131 mIBG Scans in Predicting Survival in Patients with Stage 4 Neuroblastoma,

Advances in Neuroblastoma Research conference, Stockholm, Sweden.

3. Naranjo, A., Maldonado‐Molina, M.M., Komro, K.A., Trindade, A.A., and Casella, G. (2010, August 5; Oral).

Estimation in State‐Space Models with Exogenous Covariates and Missing Data, Joint Statistical Meeting, Vancouver,

British Columbia, Canada.

4. Naranjo, A., Parisi, M.T., Shulkin, B.L., London, W.B., Matthay, K.K., Kreissman, S.G., and Yanik, G.A. (2010,

September 23; Poster). Comparison of I‐123 and I‐131 mIBG Semi‐Quantitative Scores in Predicting Survival in Patients

with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group, Children’s Oncology Group Fall 2010

Meeting, Dallas, TX.

5. Naranjo, A. (2011, March 23; Oral). Survival Tree Regression Analysis of A3961 and P9641 Patients, as part of the

Non High‐Risk Task Force presentation by Meany, H., Children’s Oncology Group Spring 2011 Meeting, Los

Angeles, CA.

6. Naranjo, A. (2016, March 4; Oral). Neuroblastoma INRGSS Risk Classification, invited presentation to UF

Department of Biostatistics faculty.

7. Naranjo, A., Irwin, M.S., Hogarty, M.D., Cohn, S.L., Park, J.R., and London, W.B. (2018, May 12; Poster). Statistical

Framework in Support of a Revised Childrenʹs Oncology Group (COG) Neuroblastoma Risk Classification System,

Advances in Neuroblastoma Research conference, San Francisco, CA.

8. Naranjo, A., Irwin, M.S., Hogarty, M.D., Cohn, S.L., Park, J.R., and London, W.B. (2019, February 19; Poster).

Statistical Framework in Support of a Revised Childrenʹs Oncology Group (COG) Neuroblastoma Risk Classification

System, University of Florida 2019 College of Medicine Research Poster Session, Gainesville, FL.

Contributed Presentations 1. Daunic, A.P., Smith, S.W., Garvin, C., Naranjo, A., Barber, B., Becker, M., Heidenescher, S., Peters, C., Taylor, G.

(2007, July; Poster). First Year Progress of a Universal Cognitive‐Behavioral Intervention for Elementary Students to

Reduce Disruptive/Aggressive Behavior, U.S. Department of Education, Institute of Education Sciences 2007 Research

Conference, Washington, D.C.

2. Daunic, A.P., Becker, M., Barber, B., Peters, C., Smith, S.W., Naranjo, A. (2007, October; Poster). Assessing teacher

behaviors that relate to socio‐emotional learning: The Multi‐Informant Teacher Assessment System, 7th Biennial

International Conference on Children and Youth with Behavioral Disorders, Dallas, TX.

3. Daunic, A.P., Smith, S.W., Naranjo, A., Garvan, C., Barber, B.R., Becker, M., Peters, C., Taylor, G., Van Loan, C.

(2008, March 27; Oral). Universal Cognitive‐Behavioral Intervention to Reduce Aggression Among 4th and 5th Grade Students: First Year Results, Annual Meeting of the American Educational Research Association, New York, NY.

4. Smith, S.W., Daunic, A.P., Naranjo, A., Garvan, C., Barber, B.R., Becker, M., Peters, C., Taylor, G., Van Loan, C.

(2008, April 2‐5; Poster). Reducing Classroom Disruptive/Aggressive Behavior: Year One Findings from a Universal/

Selective Intervention, Council for Exceptional Children – 86th Annual Convention, Boston, MA. 5. Smith, S.W., Daunic, A.P., Garvan, C., Naranjo, A., Barber, B., Becker, M., Peters, C., Taylor, G., Van Loan, C.

(2008, June 10‐12; Poster). Universal Cognitive‐Behavioral Intervention to Reduce Disruptive/Aggressive Behavior: Findings from Year 1, U.S. Department of Education, Institute of Education Sciences 2008 Research Conference, Washington, DC.


Scaruffi, P., Tonini, G.P., Noguera, R., Piqueras, M., Janoueix‐Lerosey, I., Delattre, O., Fischer, M., Oberthuer, A.,

Combaret, V., Beiske, K., Bénard, J., Ambros, P., Marques, B., Michon, J., Schleiermacher, G., Di Bernardi, B.,

Rubie, H., Cañete, A., Pötschger, U., Ladenstein, R., Hogarty, M.D., McGrady, P., London, W.B., Laureys, G.,

Speleman, F., Vandesompele, J. (2009, February 13; Poster). Improved Outcome Prediction of Children with

Neuroblastoma using a Multigene Expression Signature, a SIOPEN Study, 9th BeSHG meeting, Darwinʹs 200th Birthday,

Brussels, Belgium.

7. Escoto, H., London, W.B., McGrady, P., Naranjo, A., Li, L., Wooten‐Blanks, L., Kraveka, J.M. (2009, March 11–14;

Oral). Association of High Ceramide Levels with Unfavorable Neuroblastoma Risk Factors: A Report from the Children’s

Oncology Group, 5th International Charleston Ceramide Conference, Charleston, SC.


Scaruffi, P., Tonini, G.P., Noguera, R., Piqueras, M., Janoueix‐Lerosey, I., Delattre, O., Fischer, M., Oberthuer, A.,

Combaret, V., Beiske, K., Bénard, J., Ambros, P., Marques, B., Michon, J., Schleiermacher, G., Di Bernardi, B.,

Rubie, H., Cañete, A., Pötschger, U., Ladenstein, R., Hogarty, M.D., McGrady, P., London, W.B., Laureys, G.,

Speleman, F., Vandesompele, J. (2009, November 13; Oral). Prospective Evaluation of Molecular Signatures for Risk

Stratification in Future SIOPEN Clinical Trials, Translational Genomics in Neuroblastoma (TGiN)‐3 Meeting,

Bethesda, MD.

9. Parisi, M., Shulkin, B., Naranjo, A., McGrady, P., London, W., Kreissman, S., Yanik, G. (2010, June 5‐9; Oral).

Impact of MIBG Scores on Predicting Survival in High Risk Neuroblastoma Patients, Society of Nuclear Medicine

meeting, Salt Lake City, UT.

10. Parisi, M., Shulkin, B., Naranjo, A., McGrady, P., London, W., Kreissman, S., Yanik, G. (2010, June 5‐9; Oral).

MIBG Scores: A Means of Identifying an Ultra‐High Risk Group of Patients, Society of Nuclear Medicine meeting, Salt

Lake City, UT.

11. Yanik, G.A., Parisi, M.T, Naranjo, A., Matthay, K.K., London, W.B., McGrady, P.W., Kreissman, S.G., Shulkin,

B.L. (2010, June 7; Oral). MIBG Scoring as a Prognostic Indicator in Patients with Stage IV Neuroblastoma: A COG

Study, American Society of Clinical Oncology meeting, Chicago, IL.

12. Irwin, M.S., Naranjo, A., Attiyeh, E.F., Seeger, R., Asgharzdeh, S., Sposto, R., Ji, L., Yanik, G., Mosse, Y.P., Maris,

J.M., Park, J.R., London, W., Kreissman, S., Hogarty, M.D. (2010, June 22; Poster). Is There an Ultra‐High‐Risk

Neuroblastoma group? Report from the Children’s Oncology Group (COG) Clinical and Biological Risk Factors (CBRF)

Task Force, Advances in Neuroblastoma Research conference, Stockholm, Sweden.

13. Mestdagh, P., De Preter, K., Vermeulen, J., Naranjo, A., Bray, I., Castel, V., Chen, C., Eggert, A., Hogarty, M.D.,

London, W.B., Noguera, R., Schramm, A., Schulte, J., Stallings, R., Versteeg, R., Laureys, G., Van Roy, N.,

Speleman, F., Vandesompele, J. (2010, June 23; Oral). Improved Outcome Prediction of Children with Neuroblastoma

Using a miRNA Signature, Advances in Neuroblastoma Research conference, Stockholm, Sweden.

14. Yanik, G., Parisi, M., Shulkin, B., Naranjo, A., Kreissman, S., London, W., Villablanca, J., McGrady, P., Matthay, K.

(2010, June 24; Oral). Analyses of MIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma. A

Children’s Oncology Group Report (A3973), Advances in Neuroblastoma Research conference, Stockholm, Sweden.

15. Granger, M., Grupp, S.A., Kletzel, M., Kretschmar, C., Naranjo, A., London, W.B., and Diller, L. (2010, September

23; Poster). Feasibility of a Tandem Autologous Peripheral Blood Stem Cell Transplant Regimen for High Risk

Neuroblastoma in a Cooperative Group Setting: A Pediatric Oncology Group Study, Children’s Oncology Group Fall

2010 Meeting, Dallas, TX.

16. Irwin, M.S., Naranjo, A., London, W., Seeger, R., Yanik, G., Attiyeh, E.F., Asgharzdeh, S., Mosse, Y.P., Maris, J.M.,

Park, J., Kreissman, S., and Hogarty, M.D. (2010, September 23; Poster). Is There an Ultra‐High‐Risk Neuroblastoma

Group? : Report from the Children’s Oncology Group (COG) Clinical and Biological Risk Factors (CBRF) Task Force,

Children’s Oncology Group Fall 2010 Meeting, Dallas, TX.

17. Escoto, H., Naranjo, A., London, W.B., McGrady, P., and Kraveka, J.M. (2010, September 23; Poster). Association of

High Ceramide Levels with Unfavorable Neuroblastoma Risk Factors: A Report from the Children’s Oncology Group,

Children’s Oncology Group Fall 2010 Meeting, Dallas, TX.

18. Wang, L.L., Suganuma, R., Tovar, J.P., Naranjo, A., London, W.B., Hogarty, M.D., Gastier‐Foster, J.M., Look, A.T.,

Park, J.R., Maris, J.M., Cohn, S.L., and Shimada, H. (2011, February 26; Oral). Neuroblastoma, Undifferentiated

Subtype: A Report from the Children’s Oncology Group, Society for Pediatric Pathology Spring Meeting, San Antonio,

TX.

19. Suganuma, R., Sano, H., Wang, L.L., Tovar, J.P., Naranjo, A., London, W.B., Seeger, R.C., Hogarty, M.D., Gastier‐

Foster, J.M., Look, T.A., Park, J.R., Maris, J.M., Cohn, S.L., Amann, G., Beiske, K., Cullinane, C.J., dʹAmore, E.S.G.,

Gambini, C., Jarzembowski, J.A., Joshi, V.V., Navarro, S., Peuchmaur, M., and Shimada, H. (2011, September 30;

Oral). Peripheral Neuroblastic Tumors with Genotype‐Phenotype Discordance: A Report from Childrenʹs Oncology Group

and International Neuroblastoma Pathology Committee, Society for Pediatric Pathology Fall Meeting, Milwaukee, WI.

20. Ostler, K.R., Yang, Q., Vasanthakumar, A., Zhang, L., Looney, T.J., Naranjo, A., Salwen, H., Kocherginsky, M.,

Lahn, B.T., Cohn, S.L., and Godley, L.A. (2012, April 2; Poster). A Truncated DNMT3B Protein (DNMT3B7) Drives

DNA Methylation and Suppresses Growth in Human Neuroblastoma, American Association for Cancer Research Annual

Meeting, Chicago, IL.

21. Nuchtern, J.G., London, W.B., Barnewolt, C.E., Naranjo, A., Geiger, J.D., Cohn, S.L., and Shamberger, R.C. (2012,

April 27; Oral). A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants, a

Children’s Oncology Group Study, American Surgical Association Annual Meeting, San Francisco, CA.

22. Ehrlich, P.F., Gow, K., Barnhardt, D., Kandel, J., Hamilton, T., Chen, M., Price, M., Naranjo, A., Perlman, E.,

Dome, J., and Mullen, E. (2012, May 19; Oral). Primary Nephrectomy and Intra‐Operative Tumor Rupture: Report from

the Children’s Oncology Group (COG) Renal Tumors Committee, American Pediatric Surgery Association (APSA)

Annual Meeting, San Antonio, TX.

23. Meany, H.J., Attiyeh, E.F., Naranjo, A., Twist, C., London, W.B., Villablanca, J., Schmidt, M.L., Baker, D., Strother,

D.R., Shimada, H., Matthay, K.K., Cohn, S.L., Maris, J.M., and Park, J.R. (2012, June 3; Poster). Outcome Analysis of

Non‐High‐Risk Neuroblastoma Patients Enrolled on Children’s Oncology Group Trials P9641 and A3961, American

Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.

24. Wang, L.L., Suganuma, R., Ikegaki, N., Gastier‐Foster, J.M., Hogarty, M.D., Cohn, S.L., Maris, J.M., Naranjo, A.,

London, W.B., and Shimada, H. (2012, June 19; Oral). Prominent Nucleolar Formation and N‐myc/C‐myc Protein

Expression in Undifferentiated Neuroblastoma: Immunohistochemical Study Indicates the Worst Prognosis for the Patients

with C‐myc Positive Tumors – A Report from the Children’s Oncology Group, Advances in Neuroblastoma Research

(ANR) Conference, Toronto, ON, Canada.

25. Yanik, G., Shulkin, B., Parisi, M., Naranjo, A., Park, J., Kreissman, S., London, W., Villablanca, J., Cohn, S., and

Matthay, K. (2012, June 19; Poster). Impact of Post‐Induction Curie Scores as Prognostic Marker in High Risk

Neuroblastoma. A Children’s Oncology Group Report, Advances in Neuroblastoma Research (ANR) Conference,

Toronto, ON, Canada.

26. Yanik, G., Shulkin, B., Parisi, M., Naranjo, A., Kreissman, S., London, W., Villablanca, J., Park, J., Cohn, S., and

Matthay, K. (2012, June 19; Poster). MIBG Scoring as a Predictor of Early Relapse or Disease Related Death in High Risk

Neuroblastoma. A Children’s Oncology Group Report, Advances in Neuroblastoma Research (ANR) Conference,


27. Schmidt, M.L., Strother, D., Baker, D., Naranjo, A., McGrady, P., London, W., Shimada, H., Cohn, S., Matthay, K.,

and Maris, J. (2012, June 19; Poster). Infant Metastatic (4+ 4S) MYCN Non‐Amplified Neuroblastoma has a Very High

Survival Rate with Moderate Dose Chemotherapy, Advances in Neuroblastoma Research (ANR) Conference, Toronto,

ON, Canada.

28. Attiyeh, E., Meany, H., Naranjo, A., Twist, C., London, W., Villablanca, J., Baker, D., Strother, D.R., Schmidt, M.L.,

Maris, J., and Park, J. (2012, June 20; Oral). Outcome Analysis of Non‐High‐Risk Neuroblastoma Patients Enrolled on

Children’s Oncology Group Trials P9641 and A3961, Advances in Neuroblastoma Research (ANR) Conference,


29. Rahamanyian, M., Naranjo, A., Escoto, H., He, Y., London, W.B., Li, L., Clarke, C.J., Wooten‐Blanks, L., and

Kraveka, J.M. (2012, June 20; Poster). A Sphingolipidomic Analysis of Neuroblastoma Tumors: Implications for Novel

Therapeutic Targets, Advances in Neuroblastoma Research (ANR) Conference, Toronto, ON, Canada.


June 21; Oral). A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants, a

Children’s Oncology Group Study, Advances in Neuroblastoma Research (ANR) Conference, Toronto, ON, Canada.

31. Yanik, G., Boubaker, A., Matthay, K., Potschger, U., Naranjo, A., Shulkin, B., Gaze, M., Schmidt, M., and

Ladenstein, R. (2012, June 21; Oral). Curie and SIOPEN Scoring in Stage 4, High Risk Neuroblastoma. A Report from the

Metastatic Imaging Working Group of the International Neuroblastoma Response Criteria (INRC) Committee, Advances in

Neuroblastoma Research (ANR) Conference, Toronto, ON, Canada.

32. Batra, V., Geier, E., Martinez, D., Pawel, B., Yanik, G., Naranjo, A., Giacomini, K., Maris, J.M., Matthay, K.K., and

DuBois, S.G. (2012, June 21; Oral). Norepinephrine Transporter (NET) Protein, but not mRNA, Expression is Correlated

with Metaiodobenzylguanidine (MIBG) Avidity in Newly Diagnosed Neuroblastoma (NB) Patients: A Report from the

Children’s Oncology Group (COG), Advances in Neuroblastoma Research (ANR) Conference, Toronto, ON,

Canada.

33. Geller, J., Mullen, E., Khanna, G., Ehrlich, P., Cost, N., Naranjo, A., Dome, J., Gratias, E., and Perlman, E. (2012,

October 5‐6; Poster). Epidemiology and Characterization of Pediatric and Adolescent Renal Cell Carcinoma: A Report from

the Children’s Oncology Group Study AREN03B2, International Kidney Cancer Symposium Meeting, Chicago, IL.

34. Ehrlich, P., Cost, N., Khanna, G., Mullen, E., Gratias, E., Naranjo, A., Dome, J., Perlman, E., and Geller, J. (2012,

October 5‐6; Poster). A Description of the Surgical Experience in Children, Adolescents and Young Adults with Renal

Cell Carcinoma: A Report from the Children’s Oncology Group Study AREN03B2, International Kidney Cancer

Symposium Meeting, Chicago, IL.


October 5‐8; Poster). A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young

Infants, a Children’s Oncology Group Study, Congress of the International Society of Paediatric Oncology (SIOP),

London, United Kingdom.

36. Kawano, S., Wang, L., Naranjo, A., London, W., Hogarty, M., Gastier‐Foster, J., Look, A., Park, J., Maris, J., Cohn,

S., Seeger, R., and Shimada, H. (2013, March 2; Oral). Mitosis‐Karyorrhexis Index (MKI) and MYC Status in

Neuroblastoma, with a Special Reference to Intermediate MKI: A Report from the Children’s Oncology Group (COG),

Society for Pediatric Pathology Spring Meeting, Baltimore, MD.


P., Rodriguez‐Galindo, C., Dome, J., Perlman, E., Steen, H., and Mullen, E. (2013, April 24‐27; Oral). Prohibitin is a

Prognostic Marker of Treatment Failure and Therapeutic Target to Block Chemotherapy Resistance in Wilms Tumor,

American Society of Pediatric Hematology/Oncology (ASPHO) Annual Meeting, Miami, FL.

38. Hamilton, T.E., Barnhart, D., Gow, K., Ferrer, F., Kandel, J., Glick, R., Dasgupta, R., Naranjo, A., Gratias, E.,

Geller, J., Mullen, E., and Ehrlich, P. (2013, May 3; Oral). Quality Assurance of the Real‐Time Surgical Reviews of

AREN03B2: A COG Renal Tumor Committee Study, American Pediatric Surgical Association (APSA) Annual

Meeting, Marco Island, FL.


P., Rodriguez‐Galindo, C., Dome, J., Perlman, E., Steen, H., and Mullen, E. (2013, May 8‐10). Urine Proteomics of

Renal Tumors for Discovery of New Prognostic Markers and Therapeutic Targets, International Conference on Pediatric

Renal Tumor Biology, Bethesda, MD.

40. Wang, L.L., Kawano, S., Teshiba, R., He, L., Naranjo, A., London, W.B., Gastier‐Foster, J.M., Look, A.T., Hogarty,

M.D., Cohn, S.L., Maris, J.M., Park, J.R., and Shimada, H. (2013, September 26‐29). Age‐Dependent Prognostic Effect

by Mitosis‐Karyorrhexis Index (MKI) in Neuroblastoma: A Report from the Children’s Oncology Group, Society for

Pediatric Pathology Fall Meeting, Salt Lake City, UT.

41. Wang, L.L., Teshiba, R., He, L., Naranjo, A., London, W.B., Gastier‐Foster, J.M., Seeger, R.C., Cohn, S.L., Maris,

J.M., Park, J.R., Hogarty, M.D., and Shimada, H. (2013, November 3‐6; Poster). MYCN/MYC Protein Expression in

High‐MKI (Mitosis‐Karyorrhexis Index) Neuroblastomas: A Report from the Children’s Oncology Group, American

Association for Cancer Research (AACR) Special Conference – Pediatric Cancer at the Crossroads: Translating

Discovery into Improved Outcomes, San Diego, CA.

42. Wang, L.L., Teshiba, R., Naranjo, A., Ikegaki, N., Tang, X.X., Gastier‐Foster, J.M., Asgharzadeh, S., Seeger, R.C.,

Hogarty, M.D., London, W.B., Cohn, S.L., Park, J.R., Maris, J.M., and Shimada, H. (2014, May 13‐16; Poster).

MYCN/MYC Protein Expression in Neuroblastoma, Undifferentiated and Poorly Differentiated Subtype – C‐myc

Activation is a New Marker for Aggressive Tumor Behavior: A Report from the COG Neuroblastoma Committee, Advances

in Neuroblastoma Research (ANR) Conference, Cologne, Germany.

43. de Alarcon, P.A., London, W.B., Naranjo, A., Gorman, M., Panzer, J.A., and Matthay, K.K. (2014, May 15; Oral). A

Randomized Clinical Trial of Cyclophosphamide and Prednisone with or without Intravenous Immunoglobulin (IVIG) for

the Treatment of Neuroblastoma Associated Opsoclonus Myoclonus Ataxia Syndrome (OMA): A Childrenʹs Oncology

Group Trial, Advances in Neuroblastoma Research (ANR) Conference, Cologne, Germany.

44. Naranjo, A., Shulkin, B., Parisi, M., Park, J., Matthay, K., Glade‐Bender, J., Yu, A., and Yanik, G. (2014, May 16;

Oral). Impact of Pre‐Immunotherapy Curie Scores on Survival Following Treatment with an Anti‐GD2 Antibody (ch14.18)

and Isotretinoin in High‐Risk Neuroblastoma, Advances in Neuroblastoma Research (ANR) Conference, Cologne,

Germany.

45. Bagatell, R., McHugh, K., Naranjo, A., Van Ryn, C., Kirby, C., Brock, P., Lyons, K.A., States, L.J., Rojas, Y., Miller,

A., Volchenbaum, S., Simon, T., Krug, B., Sarnacki, S., Minard, V., Von Schweinitz, D., Kammer, B., Granata, C.,

Pio, L., Park, J.R., and Nuchtern, J. (2014, May 16; Oral). Assessment of Primary Site Response in Children with High

Risk Neuroblastoma: An International Multicenter Study, Advances in Neuroblastoma Research (ANR) Conference,

Cologne, Germany.

46. Twist, C.J., London, W.B., Naranjo, A., Schmidt, M.L., Adkins, E.S., Mattei, P., Cohn, S.L., Park, J.R., and Maris,

J.M. (2014, May 16; Oral). Maintaining Outstanding Outcomes Using Response‐ and Biology‐Based Therapy for

Intermediate‐Risk Neuroblastoma: A Report from the Childrenʹs Oncology Group Study ANBL0531, Advances in

Neuroblastoma Research (ANR) Conference, Cologne, Germany.

47. Khanna, G., Geller, J., Ehrlich, P., Servaes, S., Naranjo, A., Dome, J., Gratias, E., Perlman, E.J., Cost, N., and

Mullen, E. (2014, May 16; Oral). Renal Cell Carcinoma in Children and Adolescents: A Summary of Imaging Findings

from the Children’s Oncology Group, Society of Pediatric Radiology Annual Meeting, Washington, D.C.

48. MacLellan, D., Karakach, T., Naranjo, A., and Fernandez, C.V. (2014, May 30‐June 3). Urinary Metabolite Profiling

by Nuclear Magnetic Resonance Spectroscopy Distinguishes Control Patients from Wilms Tumor (WT) and WT Tumor by

Stage, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.

49. Mullen, E., Geller, J., Gratias, E., Perlman, E., Ehrlich, P., Khanna, G., Naranjo, A., He, Y., Hamilton, T., Ferrer, F.,

Glick, R., Gow, K., Barnhardt, D., Kandel, J., Dasgupta, R., Hoffer, F., Serveas, S., Fernandez, C., Grundy, P., and

Dome, J. (2014, May 31; Oral). Real‐Time Central Review: A Report of the First 3,000 Patients Enrolled on the Children’s

Oncology Group Renal Tumor Biology and Risk Stratification Protocol AREN03B2, American Society of Clinical

Oncology (ASCO) Annual Meeting, Chicago, IL.

50. Twist, C., London, W.B., Naranjo, A., Schmidt, M.L., Adkins, E.S., Mattei, P., Cretella, S., Cohn, S.L., Park, J.R.,

and Maris, J.M. (2014, May 31; Oral). Maintaining Outstanding Outcomes using Response‐ and Biology‐Based Therapy

for Intermediate‐Risk Neuroblastoma: A Report from the Children’s Oncology Group Study ANBL0531, American Society

of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.

51. Yanik, G.A., Naranjo, A., Parisi, M.T., Shulkin, B.L., Nadal, H., Gelfand, M., Ladenstein, R., Boubaker, A.,

Poetschger, U., Valteau‐Couanet, D., Kreissman, S.G., Park, J.R., and Matthay, K.K. (2014, June 2; Poster).

Validation of Post‐Induction Curie Scores in High‐Risk Neuroblastoma, American Society of Clinical Oncology (ASCO)

Annual Meeting, Chicago, IL.

52. Boubaker, A., Pötschger, U., Lambert, B., Castellani, M., Bar‐Sever, Z., Oudoux, A., Kaminska, A., Taborska, K.,

Biassoni, L, Kreissman, S.G., Yanik, G., Matthay, K.K., Naranjo, A., Park, J., Valteau‐Couanet, D., and Ladenstein,

R. (2014, June 2; Poster). Validation of the MIBG SIOPEN Scoring Method in Two Independent High‐Risk Neuroblastoma

Trials, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.


(2014, June 2; Poster). Historical Gold Standard for Time‐to‐Progression (TTP) and Progression‐Free Survival (PFS) from

Relapsed/Refractory Neuroblastoma Modern Era (2002‐14) Patients, American Society of Clinical Oncology (ASCO)

Annual Meeting, Chicago, IL.

54. Paulino, A.C., Gratias, E.J., Fernandez, C.V., Ehrlich, P.F., Gow, K.W., Naranjo, A., Perlman, E.J., Dome, J.S., and

Kalapurakal, J.A. (2014, September 14‐17; Oral). Outcomes and Patterns of Failure after Preoperative Chemotherapy for

Favorable Histology Wilms Tumor on National Wilms Tumor Study (NWTS)‐5, American Society for Radiation

Oncology (ASTRO) Annual Meeting, San Francisco, CA.

55. Boubaker, A., Pötschger, U., Lambert, B., Castellani, M., Bar‐Sever, Z., Oudoux, A., Kaminska, A., Taborska, K.,

Biassoni, L, Kreissman, S.G., Yanik, G., Matthay, K.K., Naranjo, A., Park, J., Valteau‐Couanet, D., and Ladenstein,

R. (2014, October 20; Oral). Validation of the MIBG SIOPEN Scoring Method in Two Independent High‐Risk

Neuroblastoma Trials, Annual Congress of the European Association of Nuclear Medicine (EANM), Gothenburg,

Sweden.

56. Mullen, E.A., Geller, J.J., Gratias, E., Perlman, E.J., Ehrlich, P.F., Khanna, G., Naranjo, A., Fernandez, C.V., Gow,

K., Ferrer, F., Hamilton, T., Glick, R., Kandel, J., Barnhart, D., He, Y., Dasgupta, R., Hoffer, F., Servaes, S., Gastier‐

Foster, J., Hill, D.A., Huff, V., Grundy, P., and Dome, J. (2014, October 23; Oral). Comprehensive Update of Pediatric

Renal Tumor Epidemiology: Analysis of the First 4000 Patients on Children’s Oncology Group (COG) Renal Tumor

Classification and Biology Protocol AREN03B2, Congress of the International Society of Paediatric Oncology (SIOP),

Toronto, Canada.

57. Ehrlich, P.F., Mullen, E., Geller, J., Naranjo, A., Gratias, E., Barnhart, D., Dasgupta, R., Ferrar, F., Gow, K.,

Hamilton, T., Kandel, J., He, Y., Perlman, E., Khanna, G., Hoffer, F., Servaes, S., Kalapurakal, J., and Dome, J.S.

(2014, October 23; Oral). Unilateral Wilms Tumor Treated by Partial Nephrectomy Enrolled on the Childrenʹs Oncology

Group (COG) Renal Tumor Biology and Classification Study AREN03B2, Congress of the International Society of

Paediatric Oncology (SIOP), Toronto, Canada.


(2014, October 22‐25; Oral). Historical Gold Standard for Time‐to‐Progression (TTP) and Progression‐Free Survival

(PFS) from Relapsed/Refractory Neuroblastoma Modern Era (2002‐14) Patients, Congress of the International Society

of Paediatric Oncology (SIOP), Toronto, Canada.


Look, A.T., Park, J.R., Maris, J.M., Cohn, S.L., Seeger, R.C., Asgharzadeh, S., and Shimada, H. (2015, January 7‐10;

Poster). Immunohistochemical Detection of MYCN Protein and MYC Protein Identifies Highly Aggressive

Neuroblastomas, AACR Special Conference on MYC: From Biology to Therapy, La Jolla, CA.

60. Yanik, G.A., Naranjo, A., Parisi, M.T., Shulkin, B.L., Nadel, H., Gelfand, M.J., Ladenstein, R., Boubaker, A.,

Poetschger, U., Valteau‐Couanet, D., Kreissman, S.G., Park, J.R., and Matthay, K.K. (2015, February 13; Oral).

Impact of Post‐Induction Curie Scores in High‐Risk Neuroblastoma, American Society for Blood and Marrow

Transplantation (ASBMT) Tandem Meeting, San Diego, CA.

61. Teshiba, R., Wang, L.L., Ikegaki, N., Tang, X.X., Naranjo, A., London, W.B., Hogarty, M.D., Gastier‐Foster, J.M.,

Look, A.T., Park, J.R., Maris, J.M., Cohn, S.L., Seeger, R.C., Asgharzadeh, S., and Shimada, H. (2015, March 21‐22;

Oral). Immunohistochemical Profile of MYCN/MYC Protein Expression in Neuroblastoma with High Mitosis‐Karyorrhexis

Index: A Report from the Children’s Oncology Group Neuroblastoma Study, Society for Pediatric Pathology Spring

Meeting, Boston, MA.

62. Galli, S., Tilan, J., Naranjo, A., Van Ryn, C., Yang, C., Tsuei, J., Trinh, E., and Kitlinska, J. (2015, March 23; Oral).

Association of Neuropeptide Y (NPY) and its Receptors with Prognostic Factors and Survival in Neuroblastoma Patients,

United States and Canadian Academy of Pathology (USCAP) Annual Meeting, Boston, MA.

63. Galli, S., Tilan, J., Naranjo, A., Van Ryn, C., Yang, C., Tsuei, J., Trinh, E., and Kitlinska, J.B. (2015, April 20; Poster). Neuropeptide Y (NPY) and its Receptor Expression in Neuroblastoma Patients – Associations with Disease Prognosis and

Patientsʹ Survival, Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, PA.

64. Oldridge, D.A., Eleveld, T.F., Bernard, V., Koster, J., Daage, L.C., Diskin, S.J., Schild, L., Bentahar, N.B., Bellini, A.,


Wei, J.S., Zhang, S., Naranjo, A., Gastier‐Foster, J.M., Hogarty, M.D., Smith, M.A., Auvil, J.G., Watkins, T.B.K.,



J., Versteeg, R., Schleiermacher, G., Maris, J.M., and Molenaar, J.J. (2015, April 21; Poster). Relapsed

Neuroblastomas Show Frequent RAS‐MAPK Pathway Mutations, Annual Meeting of the American Association

for Cancer Research (AACR), Philadelphia, PA.

65. DuBois, S.G., Temple, W., Mendelsohn, L., Kim, G.E., Nekritz, E., Gustafson, C., Lin, L., Giacomini, K., Naranjo,

A., Van Ryn, C., Yanik, G.A., Kreissman, S.G., Hogarty, M.D., and Matthay, K.K. (2015, May 31; Poster). Vesicular

Monoamine Transporter Protein Expression in Neuroblastoma: A Report from the Children’s Oncology Group, American

Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.

66. Applebaum, M.A., Henderson, T.O., London, W.B., Pinto, N.R., Volchenboum, S.L., Park, J.R., Naranjo, A.,

Pearson, A.D.J., Hero, B., Diskin, S., and Cohn, S.L. (2015, May 31; Poster). Second Malignancies in Neuroblastoma

Patients: A Report from the International Neuroblastoma Risk Group Project, American Society of Clinical Oncology

(ASCO) Annual Meeting, Chicago, IL.

67. Shusterman, S., London, W.B., Hank, J.A., Parisi, M.T., Shulkin, B.L., Servaes, S., Naranjo, A., Shimada, H., Gan,

J., Gillies, S.D., Maris, J.M., Park, J.R., and Sondel, P.M. (2015, June 1; Oral). A Feasibility and Phase II Study of the

hu14.18‐IL2 Immunocytokine in Combination with GM‐CSF and Isotretinoin in Patients with Recurrent or Refractory

Neuroblastoma: A Children’s Oncology Group Study, American Society of Clinical Oncology (ASCO) Annual


68. Nuchtern, J., Bagatelle, R., McHugh, K., Naranjo, A., Van Ryn, C., Rojas, Y., Lyons, K., Guillerman, P., Kirby, C.,

and Brock, P. (2015, October 9; Oral). A Subset of Image Defined Risk Factors Predicts Completeness of Resection in

Children with High‐Risk Neuroblastoma: An International Multicenter Study, Congress of the International Society of

Paediatric Oncology (SIOP), Cape Town, South Africa.


M.B., Sondel, P.M., Maris, J.M., Park, J.R., and Bagatell, R. (2016, June 3; Oral). ANBL1221: A Phase II Randomized

Trial of Irinotecan/ Temozolomide (I/T) with Temsirolimus (TEM) or Dinutuximab Plus Granulocyte Colony Stimulating

Factor (DIN/GMCSF) in Children with Refractory or Relapsed Neuroblastoma: A Report from the Children’s Oncology

Group (COG), American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.


Shaw, P.J., Geiger, J.D., Doski, J.J., Gorges, S.W., Khanna, G., Voss, S.D., Maris, J.M., Grupp, S.A., and Diller, L.

(2016, June 5; Oral). A Phase III Randomized Clinical Trial (RCT) of Tandem Myeloablative Autologous Stem Cell

Transplant (ASCT) Using Peripheral Blood Stem Cell (PBSC) as Consolidation Therapy for High‐Risk Neuroblastoma (HR‐

NB): A Children’s Oncology Group (COG) Study, American Society of Clinical Oncology (ASCO) Annual Meeting,

Chicago, IL.


Park, J.R., Naranjo, A., Pearson, A.D.J., Hero, B., Cohn, S.L., and Diskin, S. (2016, June 6; Poster). Second

Malignancies in Patients with Neuroblastoma: A Report from the International Neuroblastoma Risk Group Project,

American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.

72. DuBois, S.G., Mody, R., Van Ryn, C., Naranjo, A., Kreissman, S.G., Baker, D., Parisi, M.T., Shulkin, B.L., Maris,

J.M., Batra,V., Park, J.R., Matthay, K.K., and Yanik, G.A. (2016, June 6; Poster). Clinical, Biologic, and Outcome

Differences According to MIBG Avidity in Children with Neuroblastoma: A Report from the Children’s Oncology Group

(COG), American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.

73. Pinto, N.R., Emond, M.J., Spiekerman, C., Naranjo, A., Makar, K.W., Park, J.R., and McCune, J.S. (2016, June 6;

Poster). Pharmacogenetics of Treatment Response in Patients with High‐Risk Neuroblastoma: A Children’s Oncology

Group Study, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.

74. Federico, S.M., Chen, X., Easton, J., Wu, J., Mao, S., Liu, Y., Naranjo, A., Pappo, A.S., Hogarty, M.D., and Dyer,

M.A. (2016, June 6; Poster). Association of Age at Diagnosis and Stage of Disease with ATRX Mutations in

Neuroblastoma, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.

75. Granger, M., Yanik, G.A., Naranjo, A., McCune, J.S., Dubois, S.G., Bagatell, R., Weiss, B.D., Grupp, S.A., Tenney,

S.C., Asgharzadeh, S., Hogarty, M.D., Panoff, J.E., Chang, J.H., Gastier‐Foster, J.M., Mills, D., and Park, J.R. (2016,

June 6; Poster). Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients

with High‐Risk Neuroblastoma: A Children’s Oncology Group (COG) Study, American Society of Clinical Oncology

(ASCO) Annual Meeting, Chicago, IL.

76. DuBois, S.G., Mody, R., Van Ryn, C., Naranjo, A., Kreissman, S., Baker, D.L., Parisi, M., Shulkin, B., Maris, J.M.,

Batra,V., Park, J.R., Matthay, K.K., and Yanik, G. (2016, June 21; Oral). Clinical, Biologic, and Outcome Differences

According to MIBG Avidity in Children with Neuroblastoma: A Report from the Children’s Oncology Group (COG),

Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.

77. Cho, H., Yang, S., Sonawane, P., Yu, A.L., Park, J.R., Kreissman, S., Naranjo, A., Van Ryn, C., Villablanca, J.G.,

Reynolds, P., and Kang, M.H. (2016, June 21; Poster). Pharmacokinetics (PK) of 13‐cis Retinoic Acid in COG Phase III

Neuroblastoma Studies, Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.

78. Wang, L.L., Teshiba, R., Matsuno, R., Ikegaki, N., Van Ryn, C., Naranjo, A., London, W.B., Hogarty, M.D.,

Gastier‐Foster, J.M., Look, A.T., Park, J.R., Maris, J.M., Cohn, S.L., Seeger, R.C., Asgharzadeh, S., and Shimada, H.

(2016, June 21; Poster). High‐MKI Neuroblastomas ‐ MYC‐Family‐Driven Tumors with Augmented Expression of

MYCN/MYC Protein Behaves More Aggressively than Non‐MYC‐Family‐Driven Tumors: A Report from the Children’s

Oncology Group, Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.

79. Twist, C.J., Adkins, E.S., Mattei, P., Wooton‐Gorges, S.L., Hoffer, F.A., Naranjo, A., Schmidt, M.L., Hogarty, M.D.,

Irwin, M.S., Cohn, S.L., Park, J.R., Maris, J.M. (2016, June 21; Poster). Validation of Image‐Defined Risk Factor (IDRF)

Assignment in Patients with Intermediate‐Risk Neuroblastoma: A Report from the Children’s Oncology Group Study

ANBL0531, Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.



and Yanik, G. (2016, June 22; Oral). Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction

Chemotherapy for Patients with High‐Risk Neuroblastoma. A Children’s Oncology Group (COG) Study, Advances in

Neuroblastoma Research (ANR) Congress, Cairns, Australia.


Oudoux, A., Kaminska, A., Taborska, K., Biassoni, L., Parisi, M.T., Shulkin, B.L., Nadel, H.R., Gelfand, M.J., Park,

J.R., Kreissman, S.G., Valteau‐Couanet, D., Matthay, K.K., and Ladenstein, R. (2016, June 23; Oral). The Way

Towards an International mIBG Skeletal Score for High Risk Neuroblastoma: The Statistical Perspective, Advances in



Shaw, P.J., Doski, J., Geiger, J., Gorges, S.W., Khanna, G., Voss, S., Maris, J.M., Diller, L., and Grupp, S. (2016, June

23; Oral). A Phase 3 Randomized Clinical Trial (RCT) of Tandem Myeloablative Autologous Stem Cell Transplant (ASCT)

Using Peripheral Blood Stem Cell (PBSC) as Consolidation Therapy for High‐Risk Neuroblastoma (HR‐NB): A Children’s

Oncology Group (COG) Study, Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.

83. Mody, R., Naranjo, A., Van Ryn, C., London, W.B., Yu, A., Shulkin, B.L., Parisi, M.T., Serves, S., Diccianni, M.,

Sondel, P.M., Maris, J.M., Park, J.R., and Bagatell, R. (2016, June 23; Oral). Phase II Randomized Trial of

Irinotecan/Temozolomide (I/T) with Temsirolimus (TEM) or Dinutuximab Plus Granulocyte Colony Stimulating Factor

(DIN/GMCSF) in Children with Refractory or Relapsed Neuroblastoma: A Report from the Children’s Oncology Group

(COG), Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.


Park, J.R., Naranjo, A., Pearson, A.D.J., Hero, B., Cohn, S.L., and Diskin, S. (2016, June 23; Oral). Second

Malignancies in Patients with Neuroblastoma: A Report from the International Neuroblastoma Risk Group Project,


85. Pinto, N., Emond, M.J., Spiekerman, C., Naranjo, A., Makar, K., Park, J., and McCune, J.S. (2016, June 23; Oral).

Pharmacogenetics of Treatment Response in Patients with High‐Risk Neuroblastoma, A Children’s Oncology Group Study,



Maris, J.M., Bagatell, R., Park, J.R., and Hogarty, M.D. (2016, June 23; Oral). Revised Children’s Oncology Group

(COG) Risk Stratification Incorporating the International Neuroblastoma Risk Group Staging System, Advances in



Taborska, K., Parisi, M., Shulkin, B., Park, J., Kreissman, S., Matthay, K., and Ladenstein, R. (2016, October 16;

Oral). Towards an International mIBG Skeletal Score for High Risk Neuroblastoma: A SIOPEN‐COG Cooperation,

European Association of Nuclear Medicine Annual Congress, Barcelona, Spain.


Maris, J.M., Bagatell, R., Park, J.R., and Hogarty, M.D. (2016, October 21; Oral). Revised Children’s Oncology Group

(COG) Risk Stratification Incorporating the International Neuroblastoma Risk Group Staging System, Congress of the

International Society of Paediatric Oncology, Dublin, Ireland.



and Yanik, G. (2016, October 22; Oral). Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction

Chemotherapy for Patients with High‐Risk Neuroblastoma. A Children’s Oncology Group (COG) Study, Congress of the

International Society of Paediatric Oncology, Dublin, Ireland.


Taborska, K., Parisi, M., Shulkin, B., Park, J., Kreissman, S., Matthay, K., and Ladenstein, R. (2016, October 22;

Oral). The Way Towards an International mIBG Skeletal Score for High Risk Neuroblastoma: The Statistical Perspective,

Congress of the International Society of Paediatric Oncology, Dublin, Ireland.

91. Reville, P.K., Erbe, A.K., Wang, W., Carmichael, L., Kim, K., London, W.B., Naranjo, A., Hank, J.A., Diccianni, M.,

Hogarty, M.D., Park, J.R., Yu, A.L., and Sondel, P.M. (2017, February 27‐28; Poster). KIR/KIR‐Ligand Genotypes

Influence Clinical Response to Dinutuximab‐Based Immunotherapy in High‐Risk Neuroblastoma Patients, Frontiers in

Cancer Immunotherapy Meeting, New York, NY.

92. Ortiz, M.V., Burns, M., Eisenberg, A., Ahmed, S., Gaewsky, L., Bradwin, G., Cifani, P., Henssen, A., Macarthur, I.,

LaQuaglia, M., Letai, A., Naranjo, A., Gadd, S., Chi, Y., Dome, J., Perlman, E., Mullen, E., Steen, H., and Kentsis,

A. (2017, April 2; Poster). Prohibitin is a Prognostic Marker of Treatment Failure and Therapeutic Target to Block

Chemotherapy Resistance in Wilms Tumor, American Association for Cancer Research (AACR) Annual Meeting,

Washington, D.C.

93. Erbe, A.K., Wang, W., Carmichael, L., Kim, K., Reville, P.K., London, W.B., Hank, J.A., Diccianni, M.B., Naranjo,

A., Hogarty, M.D., Park, J.R., Yu, A.L., and Sondel, P.M. (2017, April 3; Poster). Impact of KIR/KIR Ligand Genotype

for Neuroblastoma Patients in a Phase 3 COG Immunotherapy Trial, American Association for Cancer Research

(AACR) Annual Meeting, Washington, D.C.

94. Cho, H., Naranjo, A., Van Ryn, C., Yang, S., Sonawane, P., Villablanca, J.G., Yu, A.L., Park, J.R., Kreissman, S.,

Reynolds, C.P., and Kang, M.H. (2017, April 3; Poster). Low Plasma Levels of 13‐Cis‐Retinoic Acid (Isotretinoin) and its

Active Metabolite 4‐Oxo‐13‐Cis‐Retinoic Acid Are Associated with Lower Overall Survival of High‐Risk Neuroblastoma

Patients, American Association for Cancer Research (AACR) Annual Meeting, Washington, D.C.


Oudoux, A., Kaminska, A., Taborska, K., Biassoni, L., Parisi, M., Shulkin, B., Nadel, H., Gelfand, M., Park, J.,

Kreissman, S., Valteau‐Couanet, D., Matthay, K., and Ladenstein, R. (2017, September 21‐23; Oral). The Way

Towards an International mIBG Skeletal Score for High Risk Neuroblastoma: The Statistical Perspective. Austrian Society

for Pediatrics and Adolescent Medicine Annual Meeting, Graz, Austria.

96. Erbe, A.K., Wang, W., Carmichael, L., Hoefges, A., Kim, K., London, W.B., Hank, J.A., Diccianni, M.B., Naranjo,

A., Hogarty, M., Park, J.R., Yu, A.L., and Sondel, P.M. (2017, November 11; Poster). Certain KIR/KIR Ligand

Genotypes Influence Patient Response to Immunotherapy in Neuroblastoma Patients, Society for Immunotherapy of

Cancer (SITC) Annual Meeting, National Harbor, MD.

97. Zeineldin, M., Federico, S., Chen, X., Xu, B., Stewart, E., Naranjo, A., Hogarty, M.D., and Dyer, M.A. (2017,

December 5; Oral). MYCN Amplification and ATRX Mutations Are Incompatible in Neuroblastoma, American

Association for Cancer Research (AACR) Special Conference: Pediatric Cancer Research: From Basic Science to

the Clinic, Atlanta, GA.

98. Zeineldin, M., Federico, S.M., Griffith, L., Jeon, J., Chen, X., Easton, J., Wu, J., Mao, S., Liu, Y., Naranjo, A., Pappo,

A.S., Hogarty, M.D., and Dyer, M.A. (2017, December 5; Oral). Synthetic Lethality Between ATRX Mutations and

MYCN Amplification in Neuroblastoma, American Association for Cancer Research (AACR) Special Conference:

Pediatric Cancer Research: From Basic Science to the Clinic, Atlanta, GA.

99. Diccianni, M.B., Mielke, J., Williams, R., Messer, K., Ozkaynak, F., Gilman, A.L., Naranjo, A., London, W., Sondel,

P.M., Park, J., Yu, A.L., and Childrenʹs Oncology Group (2018, April 17; Poster). Natural Antibodies to Non‐Human

Glycans Neu5Gc and Alpha‐Gal Correlate with Outcome of High‐Risk Neuroblastoma Patients Treated with Dinutuximab

on COG ANBL0032 and ANBL0931, American Association for Cancer Research (AACR) Annual Meeting, Chicago,

IL.

100. Desai, A.V., Guo, D., Kao, P., Shimada, H., Park, J.R., Pearson, A., Schleiermacher, G., Irwin, M., Hogarty, M.,

Naranjo, A., Cohn, S.L., and London, W.B. (2018, May 10; Poster). Loss of Information, and Confounding with Age

when using INPC for Risk Stratification: An International Neuroblastoma Risk Group Confirmatory Analysis, Advances

in Neuroblastoma Research conference, San Francisco, CA.

101. Sokol, E., Desai, A.V., Shimada, H., Park, J.R., Pearson, A.D.J., Irwin, M., Hogarty, M., Naranjo, A., Cohn, S.L.,

and London, W.B. (2018, May 10; Poster). Age, Tumor Grade, and Mitosis‐Karyorrhexis Index Are Independently

Prognostic of Outcome in Neuroblastoma: An International Neuroblastoma Risk Group Project, Advances in

Neuroblastoma Research conference, San Francisco, CA.

102. Weiss, B., Yanik, G., Naranjo, A., Fitzgerald, W., Shulkin, B., Grupp, S., Pater, L., Mattei, P., Park, J.R., and

Matthay, K.K. (2018, May 11; Oral). A Safety and Feasibility Study of 131I‐MIBG in Newly Diagnosed High‐Risk

Neuroblastoma: A Children’s Oncology Group (COG) Pilot, Advances in Neuroblastoma Research conference, San

Francisco, CA.

103. Pinto, N., Hibbitts, E., Kreissman, S., Granger, M., Irwin, M., Bagatell, R., London, W., Greengard, E., Naranjo, A.,

Park, J., and Dubois, S. (2018, May 11; Oral). Predictors of Differential Response to Induction Chemotherapy in High‐

Risk Neuroblastoma: A Report from the Children’s Oncology Group (COG), Advances in Neuroblastoma Research

conference, San Francisco, CA.

104. Diccianni, M., Ozkaynak, F., Naranjo, A., Park, J., Gilman, A., London, W., Sondel, P., and Yu, A. (2018, May 11;

Oral). Cytokine Profile and Association with Toxicities and Outcome of High‐Risk Neuroblastoma Treated with

Dinutuximab Immunotherapy on COG ANBL0931, Advances in Neuroblastoma Research conference, San Francisco,

CA.


Sondel, P.M., Glade‐Bender, J., Katzenstein, H., Maris, J., Park, J.R., and Bagatell, R. (2018, May 12; Oral). Phase II

Trial of Irinotecan/Temozolomide with Dinutuximab/GMCSF (I/T/DIN/GMCSF) in Relapsed/Refractory Neuroblastoma: A

Report from The Children’s Oncology Group (COG), Advances in Neuroblastoma Research conference, San Francisco,

CA.

106. Diccianni, M., Gilman, A., Ozkaynak, F., Naranjo, A., London, W., Cohn, S., Maris, J., Park, J., Batova, A., Messer,

K., Sondel, P., and Yu, A. (2018, May 12; Oral). Impact of Immune Cell Profiles on High‐Risk Neuroblastoma Treated

with a COG Phase III Randomized Immunotherapy Study, Advances in Neuroblastoma Research conference, San

Francisco, CA.


Sondel, P.M., Glade‐Bender, J., Katzenstein, H., Maris, J., Park, J.R., and Bagatell, R. (2018, June 2; Oral). Phase II

Trial of Irinotecan/Temozolomide/Dinutuximab/Granulocyte Macrophage Colony Stimulating Factor (I/T/DIN/GMCSF) in

Children with Relapsed/Refractory Neuroblastoma (NBL): A Report from The Childrenʹs Oncology Group (COG).

American Society of Clinical Oncology Annual Meeting, Chicago, IL.

108. Balis, F.M., Busch, C., Desai, A.V., Hibbitts, E., Naranjo, A., Bagatell, R., Irwin, M., and Fox, E. (2018, June 2;

Poster). GD2 as a Circulating Tumor Biomarker (CTB) for Neuroblastoma (NBL), American Society of Clinical

Oncology Annual Meeting, Chicago, IL.

109. Pinto, N.R., Hibbitts, E., Kreissman, S.G., Granger, M.P., Irwin, M., Bagatell, R., London, W.B., Greengard, E.G.,

Naranjo, A., Park, J.R., and DuBois, S.G. (2018, June 2; Poster). Predictors of Differential Response to Induction

Chemotherapy in High‐Risk Neuroblastoma: A Report from the Childrenʹs Oncology Group (COG), American Society of

Clinical Oncology Annual Meeting, Chicago, IL.

110. Voeller, J., Erbe, A.K., Wang, W., Feils, A., Hoefges, A., Woo, K., Wang, X., Kim, K., London, W.B., Hank, J.A.,

Naranjo, A., Park, J.R., Shusterman, S., and Sondel, P.M. (2018, October 4; Poster). Influence of KIR and KIR‐Ligand

on Patient Response in Neuroblastoma Patients in ANBL1021, Children’s Oncology Group Fall 2018 Meeting, Dallas,

TX.

111. Bona, K., Li, Y., Huang, Y., Getz, K.D., Winestone, L.E., Fisher, B.T., Desai, A.V., Hall, M., Naranjo, A.,

Henderson, T., Aplenc, R., and Bagatell, R. (2019, June 1; Poster). Poverty and Survival in Targeted Immunotherapy

Clinical Trials, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.

112. Irwin, M.S., Naranjo, A., Cohn, S.L., London, W.B., Gastier‐Foster, J., Maris, J.M., Bagatell, R., Park, J.R., and

Hogarty, M.D. (2019, June 2; Oral). Revised Children’s Oncology Group (COG) Neuroblastoma Risk Classification

System: A Report from COG ANBL00B1. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago,

IL.

113. Liu, K.X., Naranjo, A., Zhang, F.F., DuBois, S.G., Grupp, S.A., Diller, L.R., Park, J.R., and Haas‐Kogan, D.A. (2019,

Sept. 15; Oral). Role of Radiotherapy Dose‐Escalation for High‐Risk Neuroblastoma with Post‐Surgical Primary Site Gross

Residual Disease: A Report from COG ANBL0532 Study. American Society for Radiation Oncology (ASTRO) Annual


Funding History

Ongoing

“Children’s Oncology Group Statistics and Data Center”, National Institutes of Health (NIH)/National Cancer Institute

(NCI) U10 CA180899

PI: Alonzo, T. 4/23/2019–2/28/2025

Role: Co‐Principal Investigator on the subcontract from the Public Health Institute (PHI) to the University of Florida

The major goals of this project are to provide database and statistical support for COG therapeutic and biology

clinical trials.

ʺGenomic and Functional Characterization of a Panel of Neuroblastoma Patient‐Derived Xenografts and Cell Linesʺ, NIH

R01 CA221957‐01

PI: Reynolds, C. 12/15/2017–11/30/2020

Role: Principal Investigator on the subcontract from Texas Tech University Health Sciences Center to University of

Florida

The goal of this project is to enable annotation of the neuroblastoma PDX and cell line panel in the COG repository

in a fashion that will greatly facilitate selection of models to use for various biological and preclinical therapeutic

studies by the many investigators who employ these COG neuroblastoma models in their research.

ʺDiscovering Mechanisms of Neuroblastoma Tumorigenesis to Improve Patient Outcomesʺ, NIH R35 CA220500‐01

PI: Maris, J. 4/1/2018‐8/31/2024

Role: Principal Investigator on the subcontract from Childrenʹs Hospital of Philadelphia to University of Florida

The goal of this project is to determine the genetic basis of neuroblastoma to improve outcomes by understanding

the essential mechanisms of cancer formation and progression.

ʺTumor and Host Markers of Clinical Outcomes After MIBG Therapy in Neuroblastomaʺ, NIH/NCI R01 CA214912

PI: Dubois, S. 4/15/2018–3/31/2022

Role: Principal Investigator on the subcontract from Harvard Medical School to the University of Florida

The goal of this study is to determine whether biologic and genomic features of neuroblastoma patients can predict

response and toxicity from I‐131 MIBG therapy after induction chemotherapy in patients with high‐risk newly

diagnosed neuroblastoma in a large COG phase III randomized trial.

ʺMolecular Assays Defining Telomere Lengthening Mechanisms (TLM) as Neuroblastoma Prognostic Markers for

Potential Integration into a Revised COG Neuroblastoma Risk Classifierʺ, NIH/NCI U10 CA180884

PI: Reynolds, C. 3/1/2019–2/28/2020

Role: Principal Investigator on the subcontract from Texas Tech University to the University of Florida

The goal of this project is determine whether TLM status can identify patient subsets within the high‐risk group that

have divergent outcomes, especially poor (“ultra‐high riskʺ patients) or especially good outcomes.

Submitted

ʺGD2 Expression and Response to Chemoimmunotherapy in Neuroblastomaʺ, NIH/NCI

PI: Reynolds, C. 7/1/2019–6/30/2024

Role: Principal Investigator on the subcontract from Texas Tech University to University of Florida

The goal of this project is to determine the association of clinical response to GD2 expression and provide a

comprehensive set of non‐clinical and clinical data that will define the incidence of low GD2 expression in recurrent

neuroblastoma and the impact of such on response to chemo‐immunotherapy.

ʺTargeting Exportin‐1 to Eliminate Treatment Failure in High‐Risk Neuroblastomaʺ, NIH/NCI

PI: Weiser, D. 9/1/2019–8/31/2024

Role: Principal Investigator on the subcontract from Albert Einstein College of Medicine to University of Florida

The goal of this project is to improve neuroblastoma outcomes by prospectively identifying patients with ultra‐high

risk and leveraging biologic vulnerabilities to introduce novel therapies, in particular, by targeting overexpression of

the nuclear export protein Exportin‐1.

ʺPredictors of Clinical Outcomes Following MIBG Therapy in Neuroblastomaʺ, Rising Tide Foundation for Clinical

Cancer Research

PI: Bagatelle, R. 7/1/2018‐6/30/2023

Role: Principal Investigator on the subcontract from Childrenʹs Hospital of Philadelphia to University of Florida

The goal of this study is to validate tumor and host biological features that can identify groups of patients most

likely to benefit from MIBG therapy.

Completed

ʺLate Effects After High Risk Neuroblastoma – The LEAHRN Studyʺ, St. Baldrick’s Foundation

PI: Henderson, T. 7/1/2015–6/30/2019

Role: Principal Investigator on the subcontract from the University of Chicago to the University of Florida

The goal of this study is to identify a large cohort of patients with high‐risk neuroblastoma who have survived

relapse‐free long‐term following treatment in order to evaluate the late effects of therapies.


(NCI) U10 CA180899

PI: Devidas, M. 3/1/2014–2/28/2019

Role: Principal Investigator on the University of Florida subaccount

The major goals of this project are to collaborate in the design, data monitoring, and publication of childhood cancer

clinical trials and biological studies.

“The Genetic Basis of Neuroblastoma Tumorigenesis (GWAS)”, NIH/NCI R01 CA124709

PI: Maris, J. 4/1/2015–3/31/2018

Role: Principal Investigator on the subcontract from Children’s Hospital of Philadelphia to University of Florida

The goal of this project is to determine the genetic basis of neuroblastoma to improve outcomes by understanding

the essential mechanisms of cancer formation and progression and to use this knowledge to develop novel therapies.

“Isotretinoin Pharmacokinetics and Pharmacogenomics in High‐Risk Neuroblastoma”, NIH/NCI R01 CA168699

PI: Kang, M. 8/1/2013–7/31/2017

Role: Principal Investigator on the subcontract from Texas Tech University to the University of Florida

The goal of this project is to determine whether the plasma levels of 13‐cis‐RA and its metabolites achieved in high‐

risk neuroblastoma patients is associated with outcome, patient demographics and biologic characteristics, generic

formulation, and opening of the capsules for drug administration.

“Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma”, NIH/NCI R01 CA182633

PI: Asgharzadeh, S. 3/1/2015–2/28/2017

Role: Principal Investigator on the subcontract from Children’s Hospital of Los Angeles to University of Florida

The goal of this project is to validate the clinical utility of two new molecular diagnostic gene detection signatures

developed for determining prognosis and monitoring response to therapy for patients with stage 4 tumors.

“The Interactive International Neuroblastoma Risk Group [INRG] Database”, St. Baldrickʹs Foundation

PI: Cohn, S. 7/1/2013–6/30/2016

Role: Principal Investigator on the subcontract from the University of Chicago to the University of Florida

The major goal is to support the data de‐identification, clean‐up, and exports for the INRG database. This includes

data management, programming, and analytic support for other neuroblastoma biological, genomic, surgical, and

imaging projects of the COG.


(NCI) U10 CA98413

PI: Anderson, J.R. 3/1/2008–2/28/2014

Role: Co‐Investigator on the subcontract to the University of Florida

The major goals of this project are to collaborate in the design, data monitoring, and publication of childhood cancer

clinical trials and biological studies.

ʺChildren’s Oncology Group Statistics and Data Center – Neuroblastoma Virtual Tumor Bankʺ, CureSearch for Childrenʹs

Cancer

PI: Naranjo, A. 3/1/2013–2/28/2014

Role: Principal Investigator

The goals of this project are to perform novel correlative studies on recently closed neuroblastoma trials anticipated

to impact the approach to therapy of high risk disease. Collaboration on an international effort across clinical trials

worldwide to analyze the impact of these novel markers of response in predicting outcome will also be undertaken.

“Faculty Enhancement Opportunity (FEO) award”, University of Florida

PI: Naranjo, A. 12/3/2012–12/7/2012

This award was given to attend Deming Conference on Applied Statistics in Atlantic City, NJ. I attended sessions on

biomarker development, validation, and analysis; group sequential design; sensitivity analysis for missing data;

adaptive clinical trial design; and a short course on missing data in clinical trials.

“Statistics and Data Center Grant Research Supplement to Promote Diversity”, NIH/NCI U10 CA98413‐08S2

PI: Naranjo, A. 9/1/2010–2/28/2011

Role: Principal Investigator on the subcontract to the University of Florida

The goal of this project is to improve the diversity of the research workforce in scientific fields by supporting

underrepresented racial and ethnic groups. Specifically, funding from this project was used to develop an

individual research program focusing on statistical methodologies applicable to clinical trials.

“Neuroblastoma Virtual Tumor Bank”, University of Chicago

PI: Naranjo, A. 7/1/2008–12/13/2012

Role: Principal Investigator on the subcontract to the University of Florida

The major goal is to provide statistical support for the creation and maintenance of the COG Neuroblastoma Virtual

Tumor Bank (VTB). This includes specimen selection and linkage of clinical and outcome data to the specimen data.

“Universal Cognitive‐Behavioral Intervention for Elementary Students to Reduce Disruptive/Aggressive Behavior”,

National Center for Special Education Research, Institute for Education Sciences, U.S. Dept. of Education R324B060029

PI: Smith, S. 08/01/2006–07/31/2010

Role: Statistical Analyst

The major goal is to determine whether a universally applied classroom‐based curriculum can reduce disruptive/

aggressive behavior among 4th and 5th grade students, particularly those with high behavioral risk profiles.

“Neuroblastomas TARGET Initiative”, NIH/NCI U10 CA98543

PI: Reaman, G.H. 2/21/2008–2/20/2010


The major goals were to collaborate in the microarray analysis of gene expression data to identify new molecular

targets for development of novel therapies for neuroblastoma. We selected specimens from the COG Neuroblastoma

VTB database and collaborated on manuscripts and development of novel clinical trials.

“Statistical Support for COG Acute Lymphoblastic Leukemia and Neuroblastoma Clinical Trials”, Department of

Energy/National Childhood Cancer Foundation DE‐FG02‐08ER64718

PI: Reaman, G.H. 9/30/2008–9/29/2009


The major goals were to conduct statistical analysis and develop new methodologies in childhood cancer clinical

trials in the areas of acute lymphoblastic leukemia and neuroblastoma.

“Prognostic Indicators in Lupus Nephritis”, Lupus Research Institute 00018998

PI: Richards, H. 09/01/2002–07/31/2006

Role: Statistical Analyst

The major goals of this study are to learn if any immune system markers predict the development of kidney disease

in lupus patients, as well as determine if the selected markers tested over time predict whether standard treatments

are effective in treating lupus kidney disease.

COG Protocols Lead Statistician for neuroblastoma and study statistician on the following COG protocols:

ANBL00B1, ANBL00P2, ANBL00P3, ANBL0032, ANBL0531, ANBL0532, ANBL09P1, ANBL0931, ANBL1021,

ANBL12P1, ANBL1221, ANBL1232, ANBL1531, ANBL17P1, ANBL1821, ANBL19P1, ABTR01B1, ABTR04B1, and

ALTE15N2

Teaching

Course Title Credits Semester Students

GMS 6818

(co‐instructor)

Design and Conduct of Clinical Trials I 2 Spring 2010

Spring 2011

Spring 2012

Spring 2013

Fall 2013

Fall 2014

Fall 2015

8

6

12

3

10

13

13

GMS 6819

(co‐instructor)

Design and Conduct of Clinical Trials II 2 Fall 2010

Fall 2011

Fall 2012

Spring 2014

Spring 2015

Spring 2016

10

13

13

6

4

6

PHC 6022

(co‐instructor)

Design and Conduct of Clinical Trials 3 Fall 2016

Fall 2017

Fall 2018

Fall 2019

16

16

9

Guest Lectures “Power and Sample Size Analysis: A General Overview with Introduction to Case‐Control Studies and Epi‐Info”,

Feb. 19, 2009. Guest lecture in GMS 6826: Advanced Design and Methodology for Case‐Control Studies

(Instructor: Stephanie Staras).

“Power and Sample Size Analysis: A General Overview with Introduction to Case‐Control Studies and SAS Power &

Sample Size”, Feb. 11, 2010. Guest lecture in GMS 6826: Advanced Design and Methodology for Case‐Control

Studies (Instructor: Stephanie Staras).

“Clinical Trials: Phase I through IV”, July 15, 2011. Invited lecture in GMS 7093: Introduction to Clinical and

Translational Research (Moderator: Ronald Shorr).

Master’s Thesis Committees and Graduate Students

M.S. Committee Chair Hui Yan (Biostatistics, University of Florida), M.S. earned May 2013

Shuo Zhang (Biostatistics, University of Florida), M.S. earned May 2014

Anjali Thakur (M.P.H., Biostatistics Concentration, University of Florida), degree earned May 2016

Zhennan Zhu (Biostatistics, University of Florida), M.S. earned May 2017

Mingjin Liu (Biostatistics, University of Florida), transferred to Ph.D. program 2017

Ke Xu (Biostatistics, University of Florida), M.S. earned May 2019

Thuong Nguyen (Biostatistics, University of Florida), online M.S.

Hanyu Qian (Biostatistics, University of Florida), online M.S.

Vanessa Kennelly (Biostatistics, University of Florida), online M.S.

Graduate Students Ying He (Biostatistics, University of Florida), Ph.D. earned Dec. 2014. COG graduate assistant from June 2011–

December 2014. Taught how to write technical and study progress reports, SAS programming, and statistical

methodology in the areas of neuroblastoma and renal tumors for COG.

Qian Sun (Biostatistics, University of Florida), M.S. committee member, degree earned May 2016

Educational Development “Rare Paediatric Tumour Clinical Trial Design Workshop”, May 12–13, 2010, University of Birmingham, England.

The workshop brought together statisticians from COG and other international cooperative groups actively

involved in clinical trials for children with cancer to consider how to apply innovative trial methodology in the

small patient populations and relatively high survival rates encountered in pediatric oncology.

“Faculty as Teachers”, Sept. 21, 2011 – 3 hour workshop providing the essentials of teaching and learning: setting

expectations for learners, teaching skills for active learning, giving effective feedback to learners and assessing

learning. Part of the UF Health Science Center Faculty Educational Development certificate series.

“Enhancing the Lecture Format”, Oct. 19, 2011 – 1.5 hour workshop. Part of the UF Health Science Center Faculty

Educational Development certificate series.

“Teaching and Learning through Classroom Discussions”, Oct. 17, 2012 – 1.5 hour workshop exploring best practices

for facilitating discussion and how to use discussions as assessment. Part of the UF Information Technology

Teaching Excellence Workshop series.

Won the Fall 2012 University of Florida Faculty Enhancement Opportunity (FEO) award to attend the Deming

Conference on Applied Statistics in Atlantic City, NJ (Dec. 3–7, 2012). Attended sessions on biomarker

development, validation, and analysis; group sequential design; sensitivity analysis for missing data; adaptive

clinical trial design; and a short course on missing data in clinical trials.

“Communication for Managers,” Feb. 12, 2015 – 3 hour workshop identifying key issues, challenges, and strategies to

help managers communicate effectively with team members. Part of the UF Leadership Development program.

Service

COG Committees Neuroblastoma Disease, 2008–present

Neuroblastoma Steering, 2008–present

Neuroblastoma Biology, 2008–present

Renal Tumors Disease, 2010–2014

Renal Tumors Biology, 2010–2014

Young Investigators, 2009–2012

ad hoc Scientific Council concept reviewer, 2009–2011

International Neuroblastoma Clinical Trials Planning Meeting (CTPM) Metastatic Imaging Working Group, 2012–

2017

International Neuroblastoma CTPM Primary Tumor/Soft Tissue Working Group, 2012–2016

International Neuroblastoma Risk Group (INRG) Task Force, 2014–present

INRG Statistics Committee, 2018–present

Toxicity Task Force, 2018–present

University of Florida Committees College of Medicine Faculty Council, 2014–present

College of Public Health & Health Professions Faculty Council, 2011–2014

Presidential Committee, Lesbian, Gay, Bisexual, Transgender Concerns, 2010–2013

ad hoc abstract judge for College of Public Health & Health Professions Research Day, 2012–2013, 2017

College of Public Health & Health Professions Diversity ad hoc Committee, 2012–2014

University Minority Mentor, 2013

Departmental Committees Public Relations Committee, Chair, 2013–2018

Student Recruitment Committee, 2013–present

Committee to foster Biostatistics faculty mentoring opportunities in the Interdisciplinary Degree Program (IDP),

Advanced Postgraduate Program in Clinical Investigation (APPCI), and other College of Medicine student Ph.D.

and Master’s committees, 2010

Search committees to hire Research Coordinators, 2009–2010, 2012, 2013

Search committee to hire Program Assistant, 2011

Search committees to hire Statistical Data Management Analysts, 2011‐2019

Search committees to hire Ph.D. Biostatisticians, 2016‐2017

Search committee to hire Program Manager, 2016

Community Service Alachua County Public Schools science fair judge, 2009–2010, 2012

arlene h. naranjo · 2019-08-07 · publications 1. kibria, b. and naranjo, a. (2002). testing the...

Documents